Podcasts about tufts

In this episode, Matt Doherty welcomes his new co-host, New England Soccer Journal writer Sam Robb O'Hagan. The duo sits down for an early summer check-in to unpack the opening of the college recruiting window and break the news on a massive structural shift coming to the NEPSAC boys' soccer postseason. Key Discussion Topics 1. The June 15th Recruiting Window Opens Boys' Class of 2028 Insights: Sam shares his early takeaways from researching the local boys' talent pool.  The High-Ed Trend (D1 vs. D3/NESCAC): The hosts debate why local boys' players are increasingly choosing high-academic Division 3 programs (like Tufts or Amherst) over mid-tier Division 1 schools due to the transfer portal and international roster squeeze. The Girls' Talent Hotbed: Unlike the boys' side, where development timelines are more complex, local girls' commits are flying off the board to Power Four schools within the first 24 hours (including commits to Boston College and Utah). The hosts credit a highly consolidated ECNL/Girls Academy structure for better player continuity and visibility in New England. 2. Exclusive: The New NEPSAC "Open Tournament" Sam shares a major scoop regarding a postseason overhaul for NEPSAC boys' soccer starting this fall. Why the Change? The NEPSAC aims for a 35% tournament representation threshold across sports. With only 32 teams making the postseason across four classes, soccer fell short, prompting a vote to add 8 more postseason spots. The Tournament Format: Instead of introducing a fifth class, the NEPSAC is introducing an elite 8-team Open Tournament (similar to an "Elite Eight"). It will run as a single-elimination bracket alongside the existing class tournaments. Selection Process: The field will be selected by a committee of coaches, aided by an RPI-style formula looking at strength of schedule. It is expected to heavily feature top Class A and a few Class B programs. The Discourse: Matt and Sam debate the pros and cons—while it creates massive regular-season drama and an exciting playoff field, it could inadvertently dilute the prestige of the traditional Class A title. Notable Quotes "The soccer landscape in New England and just in general in the US at amateur levels is pretty freaking wild, as I've come to learn." – Sam Robb O'Hagan "The quality of play of the NESCAC is at an all-time high... the biggest winners of what's going on at the D1 level are the D3s." – Matt Doherty

Primary stroke prevention is a critical opportunity for neurologists, with most stroke risk driven by modifiable factors such as hypertension and lifestyle behaviors. This episode highlights practical tools and strategies, including Life's Essential 8 and contemporary risk calculators, while also exploring evolving approaches to shared decision making and secondary prevention. In this episode, Katie Grouse, MD, FAAN, speaks with Mitchell S. Elkind, MD, MS, FAAN, author of the article "Stroke Prevention" in the Continuum® June 2026 Cerebrovascular Disease issue. Dr. Grouse is a Continuum® Audio interviewer and a clinical assistant professor at the University of California, San Francisco in San Francisco, California. Dr. Elkind is the Chief Science Officer for Brain Health and Stroke at the American Heart Association in Dallas, Texas, and a professor of neurology and epidemiology at Columbia University in New York, New York. Additional Resources Read the article: Stroke Prevention Subscribe to Continuum®: shop.lww.com/Continuum Earn CME (available only to AAN members): continpub.com/AudioCME Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Guest: @MitchElkind Full episode transcript available here Dr Grouse: Neurologists have generally been more involved in secondary stroke prevention, but primary stroke prevention is increasingly recognized as an important topic of discussion for neurologists. Today, I have the opportunity to interview Dr. Mitchell Elkind, who wrote the article on stroke prevention in the newest Continuum issue on cerebrovascular disease.  Dr Jones: This is Dr. Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about earning CME, subscribing to the journal, and exclusive access to interviews not featured on the podcast.  Dr Grouse: This is Dr. Katie Grouse. Today, I'm interviewing Dr. Mitchell Elkind about his article on stroke prevention. This article appears in the June 2026 Continuum issue on cerebrovascular disease. Welcome to the podcast, and please introduce yourself to the audience.  Dr Elkind: Thank you so much, Katie. So, my name is Mitch Elkind, and I'm the Chief Science Officer for Brain Health and Stroke at the American Heart Association and a stroke neurologist by background.  Dr Grouse: Well, I just want to start by saying that I really enjoyed reading this article. I think this is just a really wonderful article I recommend strongly. Such a high yield, an important topic for a lot of us who see patients who are interested in learning about their stroke risks or need help with, uh, stroke prevention after having a stroke. So, I wanted to start. What's changed in the last couple of years? You know, what are some big highlights that you really want to stress that are different from maybe the last time we reviewed this topic?  Dr Elkind: Sure. Well, there's been a lot of development in the field of secondary stroke prevention, for one thing. But even beyond that, I think we increasingly appreciate how important it is to control what we call the social drivers of health on the earlier side, primordial or primary prevention. And that has been a big advance, I'd say. And I would also say, I think it's really important for neurologists to understand some of those questions about primordial and primary prevention. You know, we tend to get involved with patients after they've had a stroke or maybe a TIA, some kind of event. But sometimes we find people who are following for, you know, non-stroke related conditions who have risk factors also. And we can really play an important role in identifying those risk factors and helping to prevent a first stroke or vascular event as well. So, I think it's real important for us to be doctors even before we're neurologists. So, you know, Katie, about ninety percent of stroke risk is modifiable, so we can do a great job as neurologists in preventing stroke. And one of the most important things that we can do is to identify and treat high blood pressure. And recently, actually, the American Heart Association, American College of Cardiology guidelines on the management of hypertension have said that treatment of high blood pressure not only prevents stroke, but it can also help to prevent cognitive decline and dementia. And this is the first time that we've had a class of recommendation one and level of evidence A, the highest level of recommendation we give for the use of blood pressure treatment to prevent dementia. And that's largely based on the results of some large trials that have come out recently showing that you can prevent dementia with blood pressure control. So that's a really exciting link, I think, between cardiovascular risk factor control and subsequent brain health. It just illustrates the role that neurologists can play in, so many conditions outside of stroke as well.  Dr Grouse: That's a really great point, and I want to get a little more into the idea of primordial stroke prevention. Can you tell us a little bit more about what that might be?  Dr Elkind: So primordial prevention refers to addressing how we can prevent risk factors from occurring in the first place, and how can we improve the environments in which people live. You know, we know that only about twenty percent of health outcomes is dependent on what happens between the patient and their doctor in the office. About eighty percent of it is due to what happens in the environments in which we live, work, pray, and play. And so that's what we mean when we refer to the social drivers of health. What is the neighborhood like where somebody lives? Do they have access to healthy food? Do they have places where they can go to exercise? Is there air pollution in the area that may affect their health? You know, one really interesting fact that's become apparent in the last few years is that air pollution is a major risk factor for stroke. Something like a sixth of all strokes can be attributed to the quality of air. And so, what are the things we can do at the broader public policy, community level to reduce the risk of risk factors like high blood pressure and diabetes even before somebody has an event that brings them to the attention of the doctor? So that's what we're thinking about with regard to primordial prevention. It's the earliest stage in prevention.  Dr Grouse: And that's really fascinating. You know, I think an area that we haven't, as neurologists, really put a lot of our time thinking about, but clearly a very important thing. I really appreciated reading your article about how you incorporated the fact that, you know, a lot of these risk factors overlap very, very closely with all the risk factors for various types of cardiovascular events. And I would imagine that the work you've done as the Chief Clinical Science Officer for the American Heart Association has informed a lot of the way you've thought about-Trying to bring all these risks together and think a little bit more holistically about the whole thing. Could you tell us a little bit more about that and the work that you've done on the American Heart Association's Life's Essential 8 score?  Dr Elkind: Sure. I can't take credit for it. It's really work that was done by others at the Heart Association, particularly a cardiologist and epidemiologist named Don Lloyd-Jones. But many other volunteers participated. Life's Essential 8 is our approach to primary stroke prevention and cardiovascular prevention more broadly. We say Life's Essential 8 because it includes four health behaviors and four health factors that people can observe to reduce their risk of cardiovascular disease. The four factors are kind of things like know your numbers, your blood pressure, your blood sugar, your body mass index, right, which is a combination of weight and height, and your cholesterol level. So, know those numbers and keep them within the recommended ranges, and talk to your doctor if they're not. And then four lifestyle behaviors. So, one of them is to eat a healthy diet, and typically that means the Mediterranean diet. It means getting regular exercise, and we recommend 150 minutes a week of moderate to vigorous physical activity. Of course, it means abstinence from smoking or other tobacco products. And the last one, the eighth one, which I was so excited about when we added this, is sleep, recommending at least seven hours of sleep a night. So, I was really excited about this because we used to talk about Life's Simple 7, and then the last iteration of our recommendations included this recommendation for adequate sleep because of the mounting evidence of the importance of sleep to cardiovascular health. But sleep is really a brain function, right? And so, it was really the first, in a way, specific brain function that was added to our recommendations. So that's Life's Essential 8. People can read about it online at heart.org and recommend it to your patients as a simple way for people to understand the best approach to reducing their risk of cardiovascular disease, including stroke.  Dr Grouse: I checked it out myself after reading the article. It's very accessible to patients. It's a great education tool. And they can, you know, see their own score and use that in their own way to, to think about what their risks are and how they can help mitigate and then rescore themselves down the line. There's also, though, on the kind of more the clinician side, the PREVENT calculator as well. Could you tell us a little bit more about how we could use that in approaching this patient population?  Dr Elkind: Yeah. So, I think of Life's Essential 8 as being a patient-focused tool that people can use. PREVENT is really more for clinicians. Anybody can look it up online and enter your data into it. There's a risk calculator online. But the basic idea behind PREVENT and other similar risk calculators is that it's a way to estimate somebody's risk of having a cardiovascular event like stroke or a heart attack or even heart failure by entering information about your health. And we used to think, we used to use something called the ASCVD, atherosclerotic cardiovascular disease risk calculator, or the Framingham score. Framingham Heart Score, for example, was another one. PREVENT is the latest version, and it has several advantages over those earlier types of risk predictors. For one thing, it predicts risk at younger ages as well. It goes down to age 30. It predicts risk over a longer duration of time, so over 30, 10 or 30 years. It eliminates the use of race as an item to put into the calculator and substitutes for that socioeconomic status, so it's not a race base, but a measure of social disadvantage. And it also includes kidney elements, kidney measures. It includes renal function, for example, that weren't included in prior measures, and it can also be used to predict heart failure, which was not part of the original calculators. Another major advantage of the PREVENT study is that it was based on real-world data from about three million patients, many, many more than the 50,000 or so that the earlier risk calculators were based on. So, it has a much more robust data set and therefore allows a bit more precision in the ability to predict future risk of events. And typically, primary care doctors would enter their patient's data, calculate a risk, and then based on the results of the risk calculator, they can make recommendations about what type of medications a person should take or what other strategies they could use to reduce their risk. And so that's the role that PREVENT plays, is really being focused more for the clinician than the patient.  Dr Grouse: Really great tool for us to be aware of. You earlier alluded to the fact that neurologists are in the situation where we sometimes are helping patients with this primary prevention. But you also make a case for why it's in the patient's best interest for us to be involved in, in these conversations when we can, when we have the opportunity. Can you tell us more about that?  Dr Elkind: Shared decision-making is really important because we know that people aren't going to lead the healthiest possible lives if they're not invested in their care. And so, a doctor telling somebody what to do if the patient doesn't want to do it is gonna have limited benefit.So we emphasize the importance of shared decision-making as much as possible. And I think that where this comes up a lot is actually in the situation of, for example, atrial fibrillation, where patients will often be put on a blood thinner. And many people are fearful of blood thinners. They worry about the risk of bleeding. Maybe they know a relative who's had a bleeding complication from a blood thinner, and so they may be disinclined to try it. And so, it's really important to have these discussions about the risks and the benefits of medication and engage the patient in thinking about this. And there are even tools and visual aids that people can look to to help explain some of these complicated concepts to patients. So, these are the kinds of things that reflect implementation science as a way to improve adherence. We know what works in a clinical trial setting often, but the challenge is translating that into the real world and getting our patients to use the medications that we believe scientifically have been shown to be of benefit. I've actually been surprised sometimes at conversations I've had with people, in some cases, healthcare professionals who resist going on blood thinners because of their fear of the complications. And I feel like the evidence is there. Why don't they believe me? And that's why it's really important to have the conversation. Even our peers and colleagues can sometimes question the evidence, and it's important for us to be aware of that.  Dr Grouse: Absolutely. I think that sounds very reasonable to me, and hopefully these tools will help us with making some of these decisions with our patients. Now, turning our attention a little bit to secondary prevention. So, you know, someone's already had a stroke or a TIA, sort of thinking about what we can do to optimize their risk factors for further strokes. You know, I think there has been some changes that have happened, I think, in the last few years that might be affecting some of the decisions we're making and some of the advice we're giving our patients. I wanted to talk a little bit about GLP-1 receptor agonist medications. Is the data there to support use of this either in secondary prevention or even in primary prevention in the case of stroke?  Dr Elkind: There is evidence that supports the use of GLP-1s for stroke prevention. We need more data, though. We need trials that focus only on patients with stroke, for example, there have been studies in patients with cardiovascular disease broadly that include stroke patients. But if you look at the subcategory just of stroke patients alone, the data in that subgroup alone don't always show a benefit. And so, we need more data that's focused on stroke patients alone. So, I think the data are continuing to emerge, but we need more still.  Dr Grouse: Is there any development in the thought about whether we should be putting patients on antiplatelet therapies for incidental, incidentally identified strokes? For instance, if you got an MRI for migraine or for other reasons and you found one, no history of any stroke-like symptoms. Should we be putting these patients on aspirin or any other types of therapies?  Dr Elkind: That's a really great question. And again, it's an area where there's some controversy and really, there's really no definitive data that would support using antiplatelet therapy in people with incidentally discovered infarcts or what we call, you know, whispering strokes or silent strokes. Many stroke neurologists will use antiplatelet agents. This is one of those areas where it's so important to identify the risk factors. As we were saying before, patients who have other neurological disorders like migraine or epilepsy may turn out to have cardiovascular risk factors like diabetes and high blood pressure. That's why it's so important for neurologists to be able to treat those patients or refer them to specialists who can. Patients who have incidentally discovered lesions similarly are a group where we should be looking for risk factors. So, I don't think of it only in terms of do we put them on an antiplatelet or not, but really more holistically, can we identify their other risk factors and address those? Should the patient's information be entered into a risk calculator like PREVENT, for example, so that we can come up with a more global or holistic measure of their cardiovascular risk and address that as appropriate? Because if they are at risk for stroke, they're also at risk for cardiac events, including heart attack, heart failure, sudden cardiac arrest, and so forth. So, I think of it as a, as a great kind of teachable moment or an opportunity to catch somebody and bring them into the healthcare system more broadly and address those other potential risk factors.  Dr Grouse: Speaking of, of risk factors that we often like to think about and work up when possible, in cases where it seems certainly possible the patient had an embolic stroke, but perhaps we've done a few weeks or four weeks of cardiac monitoring, have not found any evidence of atrial fibrillation. What's new and what's the current recommendations for doing further monitoring when there's high suspicion for cardioembolic stroke?  Dr Elkind: This is a really active area of investigation, and guidelines suggest that we should do some cardiac monitoring for atrial fibrillation after an unexplained stroke, but it's not clear how much we should do. Studies generally show that the longer you follow somebody on a cardiac monitor after stroke, the more likely you are to detect atrial fibrillation. It could be as high as thirty percent after a few years. And that's great. And if you detect atrial fibrillation, people usually end up being recommended for a blood thinner. But how extensively we should monitor remains unknown. And I think a lot of the investigation recently has been around the question of, are there other ways to get that information rather than waiting six months or a year for the person to develop atrial fibrillation?It's a little bit funny logically to think a person has a stroke today, a year later you discover atrial fibrillation on the monitor, and you say, "Oh, now I know what caused your stroke a year ago." Right? The temporality, the causality perhaps is off in that case. And so, wouldn't it be better if we could tell what somebody's risk of having another cardioembolic stroke is, or the likelihood that they have atrial fibrillation is at the time that you first see them for the stroke, you know, in the hospital, for example. And so, there's some really new technologies that have evolved like AI or artificial intelligence interpretation of EKGs that can give a really good indication of which people are gonna go on to develop atrial fibrillation. And so, I think we need some more trials in that area to demonstrate that we can detect the risk of AFib and treat that even before it appears on one of those delayed monitors. That's an area that I think is very exciting right now. There's also a further question with regard to how to treat these patients, which is that sometimes atrial fibrillation is a consequence of the stroke itself. So, we can think about what people call known AF, meaning atrial fibrillation that's known about before the stroke even occurs, versus AF that's detected after a stroke, or AF-DAS, people will say. Those may have very different implications for the risk of recurrence and what the person's cardiovascular status is. So, I think what we've learned over the last few years is that atrial fibrillation, it used to be like the slam dunk for a stroke neurologist. It was the easy thing. You know, you had a stroke, you have AFib, you should be on a blood thinner. Now we know that there's lots of different kinds of AFib. There's AFib before stroke, there's AFib after stroke, there's burden of atrial fibrillation. So, some people may have 30 seconds of AFib, some people may have several hours, some people may be in it continuously. It comes and goes, and that can make it challenging to manage. So, we have a lot more work to do to understand this problem better.  Dr Grouse: That also gets me into some other interesting areas that I think there's still some question, you know, how aggressive should you be? How often is it a case of is this correlated or is this causative? For instance, when a patent foramen ovale is, is discovered in patients with cryptogenic stroke. Are there any tools or new developments to help us understand whether these PFOs should be closed in these cases?  Dr Elkind: PFO and stroke is a great story that's been going on for decades. And again, we've made tremendous progress in the last several years. So, it's true that about 20% or so of people have a PFO, and because of that, it can be really hard to say with any certainty whether an individual patient sitting in front of you, that the PFO was the cause of their stroke. Rarely we can have a really high degree of certainty. You know, if somebody has, uh, a DVT, for example, and shortly after that maybe they have pulmonary embolism and then a stroke, and we can say, "Oh, clearly this was a paradoxical embolism," went to the lungs and then some crossed over and went to the brain. That happens really infrequently. Most of the time you're faced with a patient who has a PFO and a stroke, and they may have some other risk factors. There are some tools that we can use to help figure out the likelihood that a PFO is related to a stroke. One of those is called the ROPE score or the risk of paradoxical embolism score that was developed by David Thaler and, uh, David Kent from Tufts and a group of other investigators as well. That score allows one to say what the likelihood is that the PFO was causative of the stroke, and it's based on a person's risk factors such that the younger you are, the more likely it is the PFO caused the stroke. And the absence of risk factors make it more likely that the PFO caused the stroke. So, the higher your ROPE score indicating the fewer other reasons you have a stroke, the more likely the PFO is to be causative. So that can be helpful in identifying patients who may have had a stroke due to their PFO. There are other features that are identified in something called the PASCAL score, which is a way of assessing the degree of shunting and whether or not there's an atrial septal aneurysm that can be used as additional factors that lead to the likelihood that a PFO was causative rather than just incidental. So, by putting this kind of information together, we can kind of do precision neurology or precision prevention by identifying which patients with a PFO are really the ones we need to worry about and do procedures like closure.  Dr Grouse: I look forward to hearing more and learning more as more advances are made in these areas. Dr Elkind: Thank you.   Dr Grouse: And thank you so much for joining us today to talk about your article.   Dr Elkind: Oh, I appreciate it. Thank you for giving me the opportunity. I really enjoyed it.  Dr Grouse: Again, today I've been interviewing Dr. Mitchell Elkind about his article on stroke prevention. This article appears in the June 2026 Continuum issue on cerebrovascular disease. Be sure to check out Continuum Audio episodes from this and other issues, and thank you to our listeners for joining today.  Dr Monteith: This is Dr. Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. AAN members, you can get CME for listening to this interview by completing the evaluation at continpub.com/audioCME. Thank you for listening to Continuum Audio.

TWiM visits Tufts University School of Medcine and are joined by John Coffin, Michael Malamy, and Verna Manni for a tribute to Elio Schaechter who was chair of Molecular Biology and Microbiology for 23 years.

Tufts international politics professor Dan Drezner discusses the latest deal in Iran.Boston Globe business columnist Shirley Leung joins with all the news about World Cup in Boston, and debriefs her and Jim's interview with former DA Rachael Rollins.Dr. Kate Ackerman of the Women's Health Sports and Performance Institute discusses the gap in research around women's sports health.Corby Kummer explains how international fans are unable to comprehend Taco Bell, unlimited soda refills, and more, as they come to North America for the World Cup. Plus, we as, is pickle the new pumpkin spice?And Dr. Stephen Rich, microbiology professor at UMass Amherst, joins for a tick safety segment.

Estás escuchando #JUNTOSRadio: Cuidando a nuestras familias: prevención e información sobre el sarampión. ¿Qué es y cómo se contagia? ¿Cómo se puede tratar y de qué manera podemos prevenir la enfermedad? Mitos y realidades sobre el sarampión. El Dr. Fernando Merino, Profesor Asistente de Medicina en la División de Enfermedades Infecciosas del Departamento de Medicina del Sistema de Salud de la Universidad de Kansas nos responde estas y otras preguntas. Sobre nuestro invitado: El Dr. Merino obtuvo su título de Médico en la Universidad del País Vasco, en España. Tras graduarse de la Facultad de Medicina, cursó una Maestría en Medicina Tropical en la Universidad de Valencia, también en España. Su formación en Medicina Interna tuvo lugar en el Newton Wellesley Hospital de la Universidad de Tufts, en Massachusetts. Posteriormente, completó su formación de subespecialidad en Enfermedades Infecciosas en la Universidad de Yale, en New Haven, Connecticut. Antes de trasladarse a Kansas en 2007, ejerció su profesión en dos hospitales comunitarios en los estados de Texas y Nueva York. En ambos hospitales se desempeñó como Jefe de Enfermedades Infecciosas y Presidente de los comités de Control de Infecciones y de Optimización del Uso de Antibióticos. El Dr. Merino cuenta con una amplia experiencia clínica, tanto en el tratamiento de infecciones que requieren ingreso hospitalario como en el de aquellas enfermedades que pueden ser manejadas de forma ambulatoria. Sus principales áreas de interés son las infecciones del sistema nervioso central, la infección por VIH, las hepatitis virales, las infecciones en pacientes inmunocomprometidos, las infecciones osteoarticulares, las enfermedades causadas por *Streptococcus pneumoniae* y las enfermedades prevenibles mediante vacunación. Recursos informativos en español CDC información sobre vacunación https://www.cdc.gov/measles/es/vaccines/vacunacion-contra-el-sarampion.html OPS información/ recomendaciones https://es.aft.org/childrens-health/mental-health/eating-disorders Facebook: @juntosKS Instagram: juntos_ks YouTube: Juntos KS Página web: http://juntosks.org Suscríbete en cualquiera de nuestras plataformas de Podcast: Podbean, Spotify, Amazon Music y Apple Podcast - Juntos Radio Centro JUNTOS 4125 Rainbow Blvd. M.S. 1076, Kansas City, KS 66160 Este programa es únicamente con fines educativos. Para recibir un diagnóstico o tratamiento, consulte a su médico. La información proporcionada por el invitado es responsabilidad de este. No tenemos los derechos de autor de la música que aparece en este video. Todos los derechos de la música pertenecen a sus respectivos creadores.

Singing God's Words: The Meaning and Experience of Chanting TorahDrawing from his book, Singing God's Words: The Performance of Biblical Chant in Contemporary Judaism, the first in-depth study of the meaning and experience of chanting Torah among contemporary American Jews, Rabbi Summit discusses how and why a growing number of American Jews see the chanting of Torah as one of the most authentic expressions of their religious identity.About Rabbi Jeffrey SummitRabbi Jeffrey A. Summit, Ph.D. holds an appointment as Research Professor in the Department of Music and Judaic Studies at Tufts University. He is the author of Singing God's Words: The Performance of Biblical Chant in Contemporary Judaism (Oxford University Press) and The Lord's Song in a Strange Land: Music and Identity in Contemporary Jewish Worship (Oxford University Press). His CD Abayudaya: Music from the Jewish People of Uganda (Smithsonian Folkways Recordings) was nominated for a GRAMMY award. His CD with video Delicious Peace: Coffee, Music and Interfaith Harmony in Uganda (Smithsonian Folkways Recordings) was awarded Best World Music CD by the Independent Music Awards. His research and writing focus on music and identity, music and spiritual experience, music and advocacy, and the impact of technology on the transmission of tradition. Rabbi Summit holds emeritus appointments at Tufts as Emeritus Neubauer Executive Director of Tufts Hillel and Emeritus Jewish Chaplain.

In this episode, Howard Farran sits down with Dr. Jay Reznick, a Diplomate of the American Board of Oral and Maxillofacial Surgery and one of North America's earliest adopters of fully-guided, prosthetically-based implant surgery. Trained at Tufts, USC, and L.A. County-USC Medical Center, Dr. Reznick holds both a DMD and an MD — and has spent the last two decades at the forefront of 3D digital technology in dentistry, becoming the first specialist in the U.S. to integrate CBCT and CAD/CAM into clinical practice. He is a co-founder of OnlineOralSurgery.com, a leading educational platform for practicing dentists seeking to expand their surgical skills, and a frequent lecturer and live-course instructor for dentists around the world. The conversation draws on his extensive clinical and teaching experience, exploring the evolution of implant surgery, the impact of digital workflows, and what it takes to bring advanced surgical techniques into everyday dental practice.   Episode #1705 : Dentistry Uncensored with Howard Farran, Howard sits down with Dr. Jay Reznick — oral and maxillofacial surgeon, DMD, MD, and one of the true pioneers of digital implant surgery in the United States. The first specialist in the country to integrate CBCT and CAD/CAM in practice, Dr. Reznick has spent two decades teaching dentists around the world how to think bigger, operate smarter, and deliver better surgical outcomes.

Imagine moving to a country where you didn't speak the language and had to perform on stage and TV to live audiences. Daunting? Definitely. But not only did singer, songwriter, and entertainer Gayle Tufts do just that, but she has also become Germany's best-known American and a leading cultural bridge-builder.In this engaging conversation, hosts Dan Harris and Claudia Koestler explore various themes with Gayle, including the nuances of German humor, the evolution of comedy in Germany, and her personal journey of navigating identity and belonging in a new country. The discussion also touches on the impact of political events on cultural exchange, the importance of education and the arts, and the significance of dialogue in today's world. Gayle's innovative and creative performances, highlighted by her trademark 'Dinglish', a blend of German and English, have endeared her to German audiences and made her a household name. The conversation concludes with a focus on the power of entertainment to address societal issues and foster connections across cultures. Join this entertaining, heart-warming episode, which kicks off our series on humour and comedy from around the world. Discover why laughter and song are some of the best ways to build cultural bridges and understanding during these divisive times. Check out all our episodes at overhereoverthere.org. Please don't forget to like, share, subscribe, and comment. We'd very much like to hear from you. Thank you!You can find Gayle Tufts' website and upcoming schedule at https://gayle-tufts.de/.

NBC Boston's Sue O'Connell and Trenni Casey fill infor Jim and Margery today. They talk to:Retired federal judge Nancy Gertner on a judge stopping Trump's "anti-weaponization" fund. Princeton's Khalil Gibran Muhammad on new data showing non-white students are the largest share of U.S. college enrollment. Former Massachusetts education secretary Paul Reville on AI use in schools, and planned layoffs at public schools.Tufts food policy expert Corby Kummer on the millions of people losing access to food benefits, and what was behind the collapse of veggie fast food chain Clover. 

Bil Lewis earned a Masters Degree in computer science at Indiana University in 1978, working in Integrated Development Environments and bioinformatics at Stanford, Tufts, MIT and Harvard.  He has taught at Stanford, Tufts, and MIT with a Sabbatical at L'ecole des Moines DuNanets. He is a Past District Governor for Toastmaster, an Eagle Scout, a Returned Peace Corps Officer, and an ecstatic graduate of Indiana University. Bil is talking today about his work in debugging.  Omniscient Debugging when the debugger knows everything. Bil is a frequent guest on Swimming Upstream and we fondly remember his touching interviews with the late Chief Justice Richard Guy of the Washington State Supreme Court . Bil turns his life around every few weeks, so keep watching, it will happen again soon. Learn more about your ad choices. Visit megaphone.fm/adchoices

Guster got its start in a Tufts dorm room in the early '90s. Thirty years on, they're still going strong. Cog editors Cloe Axelson and Sara Shukla caught up with Adam Gardner to talk about what it's like to have kids graduating from high school while still playing music with the friends he made all those years ago.

Originally aired on February 2, 1945. This is episode 157 of Duffy's Tavern.Become a supporter of this podcast: https://www.spreaker.com/podcast/classic-comedy-of-old-time-radio--5818299/support.Please email questions and comments to host@classiccomedyotr.com.Like us on Facebook at facebook.com/classiccomedyotr. Please share this podcast with your friends and family.You can also subscribe to our podcast on Spreaker.com, Spotify, iTunes, Stitcher, TuneIn, iHeartRadio, and Google podcasts.This show is supported by Spreaker Prime.Become a supporter of this podcast: https://www.spreaker.com/podcast/classic-comedy-of-old-time-radio--5818299/support.

Guest: Dr Nadeem Karimbux- Dean of Tufts Dental School https://www.linkedin.com/in/nadeem-karimbux-67977113   Host: Dr Serv Wahan https://www.drwahan.com/     Creating the Future of Dental Education with Dean Karimbux In this episode, Dr. Serv Wahan sits down with Tufts Dental School Dean Dr. Nadeem Karimbux to discuss the evolving landscape of dental education, tuition challenges, clinical innovation, and leadership insights. Whether you're a dental student, educator, or practitioner, discover how future trends and leadership shape the dental profession.   Key Topics: Dr. Karimbux's journey from Kenya to dean at Tufts Dental School Challenges of dental school tuition and strategies for affordability Differences and strengths among Boston's top dental schools: Harvard, Tufts, and BU The impact of facilities and clinical training in student preparedness Faculty recruitment, retention, and flexible practice models Innovations in dental education: from early wellness courses to soft skills The role of AI in dentistry: tools, diagnostics, and future potential Common mistakes new dentists make and advice on career longevity How to balance specialization dreams with the opportunities in general dentistry Leadership lessons from navigating crises and the importance of mentorship   Timestamps: 00:00 - Introduction to Dr. Nadeem Karimbux, Tufts Dental School Dean 02:43 - The benefits of Harvard's five-year curriculum and research opportunities 04:16 - The rising cost of dental education and tuition burden solutions 06:36 - Creative approaches to offset education costs, including loan forgiveness and GME funding 08:21 - Comparing Boston dental schools: strengths and unique student experiences 09:39 - Tufts' large student body and fostering collaboration across classes 11:24 - Upgrades and facilities at Tufts Dental School praised by accreditation visitors 12:47 - Path to becoming a dean and career insights into academic leadership 14:38 - Leadership during the pandemic and managing financial pressures 16:55 - Student externships, transformation, and real-world clinical experience 18:24 - The importance of lifelong connections formed during dental training 20:34 - Faculty development, part-time roles, and international faculty programs 23:49 - A typical day in the life of a dental school dean and managing crises 25:53 - International student externships and community outreach programs 28:35 - The economics of dental schools and their contribution to university budgets 30:27 - DDS vs. DMD: No real difference, just different titles 31:01 - Implant-supported dentures versus full dentures – clinical decision-making 32:36 - Oldest dental implant patients and advancements in implant dentistry 34:43 - Implants and technological innovations over the years 35:02 - Balancing dental workforce supply and demand nationally 36:14 - Advice for dental students: focus beyond technical skills for career success 39:00 - Attributes that separate good from exceptional clinicians 41:30 - Common mistakes and pitfalls for new dentists 44:30 - Staying motivated, mentoring, and pursuing continuous learning 46:12 - Dean Karimbux's legacy goals and leadership style 48:13 - The helpful role of AI in academic and clinical settings 50:29 - Future applications of AI in diagnostics and practice management 52:30 - The enduring hands-on nature of dentistry and closing thoughtsResources & Links:   Tufts Dental School, Dental School tuition, Dr Serv Wahan, Dr Wahan, Dental Students, International Dental Students This episode provides a comprehensive look at leadership and innovation in dental education, offering actionable insights for aspiring and current dental professionals.

James Walker Tufts founded Pinehurst Resort in 1895. For more than 130 years, the Tufts name has had an active role in the history and shaping of our globally recognized destination. Rick Tufts is part of that family lineage and was born and raised in Pinehurst, where he still lives. In this episode of Paradise in the Pines, Tufts talks about his family legacy, growing up in Pinehurst and how he perceives the growth and change that we are seeing inside the Home of American Golf.

Hospitals already have rich patient data. The next step is turning that data into validated, timely insights that help clinicians respond before patients deteriorate. In this episode, Brian Tufts, President & CEO at Ambient Clinical Analytics, joins Saul Marquez at the MedTech Innovator Radar Forum to explore how software-as-a-medical-device is improving critical care workflows. Brian explains how the company, a Mayo Clinic spinout, built an FDA-cleared platform that combines clinical analytics, decision support, and workflow automation to help hospitals monitor complex patients. He highlights tools like Sepsis DART, which enable earlier detection and response by embedding hospital-specific protocols directly into workflows. Brian also underscores that AI in healthcare must be validated, structured, and carefully implemented, not left to unproven models making clinical decisions. Tune in to learn how hospitals can better leverage data to improve patient care in a thoughtful, reliable way. Resources: Connect with and follow Brian Tufts on LinkedIn. Follow Ambient Clinical Technologies on LinkedIn and explore their website here.

David Delvalle began studying through the Tufts University Prison Initiative nearly a decade ago while in prison. This weekend, the 32-year-old will graduate with his bachelor's degree in civic studies and receive the presidential award for civic life.

To state the obvious nutrition is considered the cornerstone of public health, a, if not the, primary preventative measure against chronic disease. Nevertheless, the OBBBA cut SNAP funding by an estimated $187 billion; since the start of the pandemic food prices have increased by roughly 30%; and, going forward are at risk due to uncertain trade policy, global shocks including the ongoing war in Iran, water supply/access and widespread drought and other climate-related issues include the looming super El Nino event that is expected to disrupt planting cycles worldwide and breach thermal safety margins - causing most major crops to suffer further yield declines. Add to all this the questionable science behind the MAHA movement. Friedman School of Nutrition Science and Policy information is at: https://nutrition.tufts.edu/Prof Masters' bio is at: https://as.tufts.edu/economics/people/faculty/william-masters This is a public episode. If you would like to discuss this with other subscribers or get access to bonus episodes, visit www.thehealthcarepolicypodcast.com

As much as every student anticipates four or more years of perfect health during their undergraduate studies, life happens. Luckily, illness or injuries don't need to mean an end to your academic journey, especially if you know the right way to take a pause. Amy and Mike invited college advisors Jennifer Stephan and Karen Flood to explain the process of taking a medical leave of absence from college. What are five things you will learn in this episode? What is a medical leave of absence (MLOA), and how do colleges actually use medical leaves? What is the typical timeline for a leave request? How do you know when a medical leave is the right decision versus trying to push through? How do students return from a medical leave, and what are colleges really looking for in that process? What does a medical leave mean for a student's future? MEET OUR GUESTS Dr. Jennifer Stephan has held a variety of roles at top colleges and universities, including professor, academic dean, and board of admissions member, in addition to serving as a private college counselor, an alumni interviewer for Johns Hopkins University, and a parent of three. She holds a BS degree in electrical engineering from Johns Hopkins University, as well as an MS and a PhD in electrical and computer engineering from Carnegie Mellon University. Jennifer is currently the Dean of Academic Advising and Undergraduate Studies for the School of Engineering at Tufts University. Prior to joining Tufts in 2016, she spent over two decades serving as a dean and a professor of Computer Science at Wellesley College, where she collaborated with colleagues at MIT, Olin College of Engineering, and Babson College to support students pursuing engineering. While at Wellesley, Jennifer served on the College's Board of Admissions, reading and evaluating approximately one hundred transfer applications each year. Jennifer is also the founder of Lantern College Counseling, a robust college counseling practice where she regularly draws on insights from her experience leading in higher education to help students develop their college lists and shape competitive, authentic applications. Jennifer specializes in STEM, computer science, engineering, undecided, and transfer students. She is a member of the National Association for College Admissions Counseling (NACAC) and a professional member of the Independent Educational Consultants Association (IECA). Jennifer appeared on the podcast in episode 620 to discuss ARTIFICIAL INTELLIGENCE AS AN UNDERGRADUATE MAJOR: WHAT YOU NEED TO KNOW, in episode 541 to discuss NAVIGATING THE COMPETITIVE LANDSCAPE OF COMPUTER SCIENCE AND ENGINEERING ADMISSIONS, and in episode 559 for an IEC Profile. Find Jennifer at jennifer@lanterncollege.com or https://www.lanterncollegecounseling.com. Dr. Karen Flood is the founder of Riverside College Coaching, LLC, which provides one-on-one support to help students thrive in college. With deep insider knowledge of universities, Karen supports students in their transition to college-level academics, helping them develop organizational and time-management skills and a stronger sense of self-efficacy.  Before founding Riverside College Coaching, Karen spent three decades at Harvard University as Associate Dean of the Harvard Summer School, a Resident Dean of Harvard College, Director of Undergraduate Studies, First-Year Adviser, and Lecturer. In these roles, she counseled hundreds of students navigating academic and personal difficulties.  Karen has a BA from Yale University and a PhD from Harvard University and has received multiple teaching distinctions at Harvard, including the Jan Thaddeus Teaching Prize. Karen can be reached at karen@riversidecollegecoaching.com. LINKS Medical Leave of Absence in College: What Families Need to Know About Readiness, Documentation, and Return Know Your Rights: Leave of Absence Policies in Higher Education RELATED EPISODES HOW TO PERSIST TO COLLEGE GRADUATION COLLEGE TRANSITIONS AND DISTRESS TOLERANCE MAKING THE MOST OF COLLEGE SUPPORT SYSTEMS ABOUT THIS PODCAST Tests and the Rest is THE college admissions industry podcast. Explore all of our episodes on the show page. ABOUT YOUR HOSTS Mike Bergin is the president of Chariot Learning and founder of TestBright, Roots2Words, and College Eagle. Amy Seeley is the president of Seeley Test Pros and LEAP. If you're interested in working with Mike and/or Amy for test preparation, training, or consulting, get in touch through our contact page.  

Tara Stoinski (A Gorilla Story) is a primatologist, conservationist, and CEO and Chief Scientific Officer of the Dian Fossey Gorilla Fund. Tara returns to the Armchair Expert to discuss growing up outside Philadelphia, her academic path from Tufts to Oxford to Georgia Tech, and balancing motherhood with a career studying gorillas in Rwanda. Tara and Dax talk about documenting rare gorilla dominance battles, the challenges of filming endangered animals in the wild, and how gorilla social structures differ from chimpanzees. Tara explains the importance of long-term behavioral research, how early life trauma can impact animal behavior, and why strong social bonds are key to survival in both gorillas and humans.Take printer ink off your to-do list with HP Smart Tank | hp.com/SmartTankCheck Allstate first for a quote that could save you hundreds: https://www.allstate.com/See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Kim Case, a longtime Portland Art Gallery artist, returns to Radio Maine to reflect on the evolution of her painting practice and her deepening exploration of abstraction. Trained in photography and art history at the School of the Museum of Fine Arts and Tufts, Case began with a focus on realism but has increasingly embraced abstraction as a way to express emotion, energy, and the subtle presence of human experience in nature. In this conversation, she shares how life changes—from raising a teenage son to adapting to new studio spaces—have shaped both her process and perspective. Case discusses the importance of light, discipline, and treating art as a professional practice, while also trusting intuition through the highs and lows of creation. Her work, rooted in New England landscapes, now pushes toward a more expressive, vibrant visual language. Join our conversation with Kim Case today on Radio Maine—and be sure to subscribe to the channel.

Donate (no account necessary) | Subscribe (account required) Join Bryan Dean Wright, former CIA Operations Officer, as he dives into today's top stories shaping America and the world. In this Monday Headline Brief of The Wright Report, Bryan covers a shocking attempted assassination of President Trump at the White House Correspondents' Dinner, raising urgent questions about Secret Service failures and the broader climate of political violence in America. He breaks down how the suspect gained access to the hotel with weapons, the security breakdowns that allowed him to get dangerously close to the President and his cabinet, and the political and cultural factors that may be fueling rising threats. Bryan also examines national reactions and what this moment could signal about the stability of U.S. institutions and public safety moving forward. Plus, Bryan delivers key updates on the war with Iran, including stalled peace talks, covert U.S. operations targeting Iranian naval threats, and new signs of deepening cooperation between Israel and Arab nations. He also covers a surge in U.S. energy exports, looming fuel shortages in the western U.S., immigration policy shifts, rising crime trends in Washington, D.C., and a developing agricultural threat from screwworm infestations.   "And you shall know the truth, and the truth shall make you free." - John 8:32     Keywords: Trump assassination attempt 2026 White House Correspondents Dinner security failure, Secret Service breach Hilton Hotel Washington DC investigation, political violence US polarization threats analysis, Iran war update peace talks collapse covert operations Strait of Hormuz, Israel UAE cooperation Iron Dome Middle East alliances, US energy exports record LNG crude oil markets 2026, West Coast fuel shortage forecast diesel jet fuel crisis, immigration policy denaturalization DOJ expansion 2026, screwworm outbreak US Mexico cattle crisis agriculture impact, vitamin D diabetes prevention research Tufts study, Bryan Dean Wright podcast, The Wright Report

In this episode, hosts David, Flora, and Elizabeth are joined by Alice from the Tufts Drag Collective. Join them as they experiment with drag makeup while exploring the rich history of drag, its political significance, its evolving role in pop culture and media, and it's presence at Tufts!To learn more about Tufts Sex Health Reps, visit:⁠⁠⁠⁠SHR Instagram⁠⁠⁠⁠⁠⁠⁠⁠SHR Linktree⁠⁠⁠⁠ To learn more about Tufts CARE Office, visit:⁠⁠⁠⁠CARE Website⁠⁠⁠⁠⁠⁠⁠⁠CARE Instagram⁠⁠⁠⁠ 

“The awareness of how lifestyle, diet, and exercise affect us is mind-blowing.” Dr. Giovanni Campanile and Dr. Sandra Cammarata are the founders of CorAeon, the only functional medicine practice founded and led by a husband-and-wife team. Campanile is a Harvard-trained functional cardiologist, Associate Professor of Medicine at Rutgers, New Jersey Medical School, and former cardiologist for the President of the United States, George H.W. Bush. Cammarata is a Tufts-trained functional psychiatrist with 36 years of experience and multiple Castle Connolly Top Doctor honors. Together, they treat cardiovascular health and mental well-being as one inseparable system. They are co-authors of The Sicilian Secret Diet Plan and hosts of the podcast The Rest is Health. 00:00 - The mind-body approach to heart health 03:01 - How relationships predict lifespan 05:18 - The Monday morning heart attack 09:13 - Where healthy people get tripped up 13:02 - Visceral fat & body composition testing 15:28 - Biomarkers beyond cholesterol 23:25 - The problem with a zero CAC score 25:09 - Medications for heart disease risk 28:22 - When stress is the real driver 31:46 - EXO Mind & magnetic brain stimulation 35:34 - The problems with traditional cardiology 41:00 - The benefits of sauna therapy 44:46 - The hidden epidemic: insulin resistance 47:57 - The future of heart health Referenced in the episode:  Harvard longevity study: https://www.adultdevelopmentstudy.org/  This podcast is sponsored by CorAeon, the only functional medicine practice created by a functional cardiologist and functional psychiatrist team for a true mind-body approach. Learn more at coraeon.com.  We hope you enjoy this episode, and feel free to watch the full video on YouTube! Whether it's an article or podcast, we want to know what we can do to help here at mindbodygreen. Let us know at: podcast@mindbodygreen.com. Learn more about your ad choices. Visit megaphone.fm/adchoices

Read the full transcript here. How do we tell the difference between a theory that is incomplete and a theory that is simply wrong? What should count as success in fundamental physics when direct experiments are scarce? Can a theory be scientifically valuable long before it becomes directly testable? What does it mean for string theory to be both a candidate description of reality and a powerful mathematical toolkit? How often do people conflate the usefulness of a framework with proof that it describes the world? Can a theory be deeply generative even if it never becomes the final answer? What should we make of ideas that produce insights across mathematics, black holes, quantum fields, and condensed matter without yet pinning down our universe? Is there a meaningful difference between string theory as a family of possibilities and string theory as the true structure of nature? When a framework can describe many possible universes, is that a strength or a failure of specificity? Why has elegance been such a powerful guide in physics? When is beauty a fruitful heuristic, and when is it a dangerous seduction? Do humans mistake their own aesthetic preferences for clues about reality? Why have some of the strangest successful theories also turned out to be the most conceptually beautiful? How fair is the criticism that string theory was oversold? When promising frameworks fail to deliver quick experimental confirmation, how much hype should they be allowed to survive? Do fields become distorted when bold public narratives outrun what the evidence can support? How much do sociology, prestige, and intellectual fashion shape what physicists work on? Links: Christian's YouTube Channel Christian's work on ResearchGate and Google Scholar Christian Ferko studied math and physics at MIT before completing his PhD at the University of Chicago, focusing on string theory. He then performed postdoctoral research at the University of California, Davis, at the Center for Quantum Mathematics and Physics. Christian currently holds a joint appointment at Northeastern University and as a Junior Investigator at the Institute for Artificial Intelligence and Fundamental Interactions, a collaboration between MIT, Harvard, Northeastern, and Tufts. His research interests include string theory, quantum field theory, classical and quantum gravity, and the intersection between physics and AI. Staff Spencer Greenberg — Host + Director Ryan Kessler — Producer + Technical Lead WeAmplify — Transcriptionists Igor Scaldini — Marketing Consultant Music Broke for Free Josh Woodward Lee Rosevere Quiet Music for Tiny Robots wowamusic zapsplat.com Affiliates Clearer Thinking GuidedTrack Mind Ease Positly UpLift [Read more]

Growing up, Valencia Koomson wasn't supposed to be the one playing with the electronic set - that was her brother's Christmas present. She played with it anyway, and now she runs a lab at Tufts University focused on designing precision biosensors. She's turned that expertise toward addressing a long-overlooked problem in medical technology: pulse oximeters that work less reliably for patients with darker skin.In this episode, she explains what it actually takes to engineer a more inclusive pulse oximeter and she shares how she's navigating the complexities of commercialising a new medical device.You'll learn:- Why pulse oximeters tend to be less accurate on patients with darker skin tones- The engineering principles Koomson is using to redesign the device from the ground up- How she thinks about bridging the gap between lab innovation and real-world impact---*** Help us shape the future of Made For Us! Take our 4-minute listener survey for the chance to win a $25 Amazon Gift Card and get instant access to our curated reading list of every book ever recommended on the show: https://forms.gle/pNyrCooa23oYsaVk7---About Valencia KoomsonValencia Koomson holds the position of Associate Professor in the Department of Electrical and Computer Engineering at Tufts University with a secondary appointment at the Department of Computer Science and Tisch College of Civic Life. She is the founding director of the Advanced Integrated Circuits & Systems Lab at Tufts with a research focus on medical device innovation, global health technology, and health equity advocacy. Dr. Koomson completed B.S. and M.Eng. degrees in electrical engineering and computer science at MIT. She was awarded the George C. Marshall scholarship to pursue post-graduate studies at the University of Cambridge where she received the M.Phil. and Ph.D. degrees in electrical engineering. Dr. Koomson has authored over 60 publications, book chapters, and patents. She was awarded the Dr. Martin Luther King Jr. Visiting Professorship at MIT in 2021.Follow Valencia Koomson on LinkedIn: https://www.linkedin.com/in/profkoomson/Learn more about the Advanced Integrated Circuits and Systems Lab at Tufts: https://engineering.tufts.edu/ece/koomson---Other episodes you might like:The pulse oximeter problem: a trusted medical device comes under the spotlightHow to design a fairer healthcare system---Connect with Made for Us- Show notes and transcripts: https://made-for-us.captivate.fm/- LinkedIn: https://www.linkedin.com/company/madeforuspodcast- Instagram: https://www.instagram.com/madeforuspodcast- Newsletter: https://madeforuspodcast.beehiiv.com/

A trove of police body camera video is providing a new window into last month's controversial immigration raid in South Burlington. A Tufts university student detained by ICE last year after writing a pro-Palestinian op-ed has settled her case with the federal government. And the Vermont legislature is clarifying what towns can control when it comes to farming after a surprise state Supreme Court decision last May. Plus, Vermont is one of six New England states weighing new legislation to make it easier for people to own and install small, plug-in solar panels.

The Enlightened Family Business Podcast Ep. 158: You Can't Lead the Next Generation If You're Not Around For It — Dr. Mark Su on Longevity   In this episode of the Enlightened Family Business Podcast, host Chris Yonker sits down with Dr. Mark Su, functional and longevity medicine physician, founder of RootSeek Health and True Wellness Clinic in New England, for a wide-ranging conversation on what it actually means to take authority over your own biology. Dr. Su breaks down the three-category framework he uses in his longevity practice — age-related diseases, cellular root causes of aging, and lifestyle factors anchored by muscle health — and explains why your biologic age matters far more than your chronological one. They explore the groundbreaking science behind epigenetics, telomere health, biologic age testing, and VO2 max, and why moving just one category in your VO2 max ranking is statistically more protective than quitting smoking or eliminating heart disease. Dr. Su also tackles the overwhelm of the longevity information landscape, the critical role of self-advocacy in healthcare, the underappreciated connection between trauma, ACE scores, and chronic disease, and where AI fits — and doesn't — in helping individuals prioritize their health. A conversation for driven family business leaders who are ready to invest in their most important asset: themselves. Episode Chapters ·       4:40   Meet Dr. Mark Su ·       8:07   Why Longevity Is Having a Moment ·       12:03  Genetics vs. Epigenetics: How Much Authority Do You Have? ·       17:29  The Three Categories of Longevity Medicine ·       27:36  The Four Horsemen: Age-Related Diseases ·       29:00  Cellular Root Causes of Aging: Telomeres, Biologic Age, and Immunity ·       32:00  Muscle as Your Longevity Organ and the VO2 Max Breakthrough ·       35:47  Testing: What's Available, What's DIY, and What Requires a Doctor ·       41:44  Trauma, ACE Scores, and the Stress-Longevity Connection ·       47:38  How to Find the Right Practitioner ·       53:00  The Role of AI in Personalizing Your Health ·       57:37  Hyperbaric Chambers and Emerging Treatments ·       58:46  Resources and Farewell   Websites ·       drmarksu.com ·       rootseekhealth.com ·       truewellnessclinic.com ·       chrisyonker.com   About Dr. Mark Su Dr. Mark Su is a functional and longevity medicine physician with over a decade of practice experience in New England. He is the founder of RootSeek Health, a virtual practice specializing in chronic inflammation and longevity medicine with no geographic boundaries, and a co-founder of True Wellness Clinic, a brick-and-mortar longevity clinic offering in-person procedural treatments including hyperbaric oxygen therapy and IV ozone. Trained at Tufts and deeply influenced by the pioneering biological age research of his wife, Dr. Jessica Su of Harvard, Dr. Mark Su brings a systems-level, root-cause approach to helping patients understand where they are biologically — and what they can actually do about it. His work bridges chronic disease, longevity science, and the belief that every person deserves a clear map for living their healthiest, fullest life.

How can schools help students practice democracy—not just learn about it? In this episode of the Time for Teachership Podcast, host Lindsay Lyons sits down with civic education researcher Dr. Sarah Burnham to explore how classrooms can cultivate the habits of democracy, civic engagement, and critical consciousness in young people. Dr. Burnham, a researcher at Center for Information and Research on Civic Learning and Engagement (CIRCLE) at Tufts University, shares insights from research on civic education, student belonging, and anti-oppressive attitudes in youth. Together they discuss why civic learning must move beyond memorizing government structures to include student voice, inquiry-based learning, participatory decision-making, and real-world civic action. You'll hear powerful examples of schools using participatory budgeting, collaborative decision-making, and student-led initiatives to strengthen school communities and foster civic identity. Dr. Burnham also explains how families can support civic development at home through everyday conversations, community involvement, and modeling respectful disagreement. If you're an educator, school leader, or parent who wants to empower young people to see themselves as active participants in democracy, this episode is packed with research-backed strategies and inspiring ideas.   Key Topics in This Episode What it means to build the habits of democracy in classrooms Why student belonging and representation are critical for civic learning The research behind critical consciousness and anti-oppressive attitudes How inquiry-based civic education strengthens engagement and agency Examples of participatory budgeting in schools The role of student voice and shared decision-making Why civic education does not lead to political indoctrination How families can support youth civic engagement at home   Get Your Episode Freebie & More Resources On My Website: https://www.lindsaybethlyons.com/blog/253   Connect with guest Dr. Sarah Burnham BlueSky: BernhamBurglar LinkedIn: SL Burnham Email: sarah.burnham@tufts.edu Research hub: CIRCLE at Tufts

Dr. Lawrence Uricchio is Assistant Professor and the Youniss Family Professor of Innovation in the Department of Biology at Tufts University. Research in Lawrence's lab focuses on modeling how evolutionary and ecological processes work. They use a combination of experimental and observational approaches to generate data, and then they develop mathematical models to explain the observations they make in nature. Outside of work, Lawrence is a devoted family man who loves spending time with his nine-year-old son, often shuttling him between soccer practices and games. He also enjoys being outdoors and running, a passion that has stayed with him since his days as a middle-distance runner in high school and college. He completed his bachelor's degree in physics at Carleton College, received master's degrees in biophysical sciences and computer science from the University of Chicago, and was awarded his PhD in bioinformatics from the University of California, San Francisco. While at UCSF, he was named a Discovery Fellow. Afterwards, Lawrence conducted postdoctoral research at Stanford University under a Center for Computational, Evolutionary and Human Genomics (CEHG) Fellowship and an NIH Institutional Research and Academic Career Development Award (IRACDA). He also conducted postdoctoral research at the University of California, Berkeley before joining the faculty at Tufts in 2021. In this interview, Lawrence shares more about his life and science.

Princeton University professor of African American Studies and Public Affairs, Khalil Gibran Muhammad, discusses the Trump admin's newest investigations into Harvard. And we check in on the broader higher ed crackdown.Tufts food policy expert Corby Kummer explains how the war in Iran is impacting your grocery bill, and how Big Food continues to push back against the MAHA food policy agenda. Retired federal judge Nancy Gertner preview's the birthright citizenship case in front of the U.S. Supreme Court this week, and weighs in on the case of a 98-year-old federal judge who won't give up her seat.

Tufts food economist Dr. Sean Cash explains why the new dietary guidelines raised eyebrows, why a new Farm Bill is unlikely this Congress, and why defining "ultra-processed food" is harder — and more important — than it sounds.

Friday marked National Match Day for medical students. WBZ NewsRadio's Mike Macklin reports. See omnystudio.com/listener for privacy information.

Dr Deb Muth 00:03Well, welcome back to Let’s Talk Wellness Now. I am your host, Dr. Deb. And what is the most talked-about peptides in functional medicine? aren’t actually FDA approved. Not because they don’t work, but because no one’s funded the research to prove it yet. The truth is, some of the compounds that dominate wellness forums, BPC-157, TB-500, thymosin beta-4, epitalin, occupy a fascinating space between breakthrough science and unregulated experimentation. In today’s episode, we’re stepping into that grey zone, the world of investigational peptides, to separate mechanism from marketing. I’m going to walk you through the science that actually shows and where it stops, how to evaluate claims when human data don’t yet exist, and the quality, purity, and safety red flags that you need to recognise. Dr Deb Muth 01:06I created it in a previous episode, so go check that one out. And why honesty is the most important prescription in peptide medicine. If you’ve ever wondered whether these research-only peptides are the frontier of healing or the next functional medicine fad, this episode is for you. So grab your cup of tea or coffee, get comfortable, and let’s talk about what it really means to use peptides that are promising but still under investigation. So we’re going to break just for a second here and have a word from our sponsor. It is because of them that we stay on the air. So thank you for this. And we will be right back. Did you know sweating can literally heal your cells? Infrared saunas don’t just relax you. They detox your body, balance hormones, and boost mitochondrial energy. I’m obsessed with my Health Tech sauna. And right now, you can save $500 with my code at healthtechhealth.com slash dr-muth-req-25. Dr. Deb Muth 02:15All right, guys, welcome back. Let’s dive into investigational peptides, the evidence gap. So the following peptides we’re about ready to discuss are extensively in integrative, functional, and regenerative medicine circles. They may have intriguing mechanisms and promising preclinical data. However, they lack FDA approval, and the evidence quality varies dramatically. from interesting preliminary research to essentially no human data at all. And this distinction is really critical for maintaining scientific integrity. So let’s talk about immune-modulating peptides. There’s thymus and alpha-1, and this is an international story on the thymic peptides. Thymusin alpha-1, known as TA1, is marketed internationally as zidaxin. Dr. Deb Muth 03:16It’s a 28-amino acid polypeptide originally isolated from thymusin fraction 5, which was extracted from bovine thymus tissue. Modern production uses synthetic peptide synthesis. The thymus gland is located behind the sternum and is the primary site for T cell maturation, and thymic peptides like TA1 play roles in human system development and regulation. Now, I love thymus peptides. I love thymus glandular products. I’ve used thymus glandular products for decades. Ground-up animal thymus gland is basically what it is. There are a couple of different supplement companies that I’ve used over the years that are amazing with this. And they do a fantastic job, and they really do help to support the immune system. So when thymus peptides came out, it was really exciting because it took the whole idea of thymus support to a new level. Dr. Deb Muth 04:17The mechanism actually behind the thymus in alpha-1 is complex and involves multiple aspects of immune function. At the cellular level, TA1 enhances T cell maturation and differentiation, particularly the development of helper T cells and cytotoxic T cells. It modulates T cell receptor expression and can influence the balance between Th1 cell-mediated immunity and Th2 humoral immunity responses. And it also enhances the natural killer cell activity and modulates dendritic cell function, which are critical for antigen presentation. and initiation of adaptive immune responses. And on the cytokine level, TA1 influences production of interleukin-2, IL-2, interferon gamma, IFN-γ, and interleukin-10, IL-10. Dr. Deb Muth 05:19These create immune modulatory rather than simple immune stimulatory effects. This is a very important distinction because TA1 appears to help balance the immune system rather than simply ramping this up, which theoretically makes it safer in conditions where immune overstimulation would be a problem, such as an autoimmune disease. Hashimoto’s, autoimmune, lupus, Sjogren’s, any of those autoimmune diseases, we don’t want to overstimulate their immune system. So you want to use a product like this that’s non-stimulating. Now, the regulatory status on TA1 is geographically variable and represents one of the challenges in discussing this peptide with patients. It is not FDA-approved in the United States. However, it is approved in several other countries for specific conditions. Dr. Deb Muth 06:19In Italy, it’s approved for the treatment of chronic hepatitis B and hepatitis C. In China, it’s approved for chronic hepatitis B and adjunct immune compromised patients receiving vaccinations or suffering from certain infections. It has an orphan drug designation in the United States for certain cancer indications, but its designation does not constitute approval. It simply provides regulatory incentives for further development. So the evidence base for thymosin alpha-1 is substantial in some areas but comes primarily from non-US populations and research groups, which creates challenges in evaluating quality and generalizable information. So in hepatitis B and C, multiple clinical trials, many conducted in China and Italy, have examined TA1 as an adjunct to antiviral therapy. Dr. Deb Muth 07:21A meta-analysis by Wu and colleagues published in the Journal of Viral Hepatitis in 2013 examined 23 randomized controlled trials, including over 2,000 patients with chronic hepatitis B. The analysis found that combining TA1 with nucleoside analogs like LAMVDUDE or an and TCAVAR improved the hepatitis antigen seroconversion rates by HBV DNA clearance compared to its nucleoside analogs alone. And the effect sizes were modest but statistically significant, with the HBE-AG seroconversion rates improving from about 24% with antivirals alone to 38% in combined therapy. Now in hepatitis C, early trials before the development of direct-acting antivirals showed that TA1 combined with interferon alpha improved sustained virological responses, and compared to interferon alpha, Dr. Deb Muth 08:30Furon alone, particularly in difficult-to-treat populations like those with a genotype one or a high viral load. However, the advent of highly effective direct acting antivirals that achieve SRV rates, sorry, SVR rates exceeding 95%, the role of TA1 in hepatitis C has become less clear. Now in sepsis and critical illness, more recent interest has focused on TA1 in severe cases of sepsis and septic shock. Ren and colleagues published a systematic review and meta-analysis in the Frontiers of Immunology in 2022, analyzing 18 randomized controlled trials, including 1787 patients with severe sepsis or septic shock the pooled analysis showed that ta1 administration was associated with reduced 28-day mortality relative risk at 0.70 meaning a 30 reduction in mortality compared to the standard care alone and the effect appeared Dr. Deb Muth 09:39most pronounced in patients with sepsis-induced immunosuppression measured by HLA-DR expression in monocytes. Now, this is amazing because going forward, we’re going to talk about something that’s commonly known as cytokine storm. Now, cytokine storm really became apparent since 2020 with the viral infection that we’re dealing with in the world today. But they were already looking at this kind of cytokine storm produced by sepsis or sepsis-induced immunosuppression. And it triggered this hyperinflammatory response called the cytokine storm. And many patients who survived the initial phase of the immune suppressed stata, characterized by a T cell exhaustion, reduced antigen presentation, and increased susceptibility to secondary infections. Thymusin alpha-1, TA1, may help restore this immune competence in this phase. However, it’s important to note that patient selection and timing are critical. Dr. Deb Muth 10:43Giving this immune stimulant during a hyperinflammatory phase could theoretically worsen outcomes. So you don’t want to give it to them while they’re in the flare up or the sepsis or the infection, but given to them during the immunosuppression phase afterwards might be beneficial. Now there is also some cancer immunotherapy that we see with TA1 and has been studied as an adjunct in cancer treatment with the hypothesis that it could enhance immune surveillance and response to tumors. And a comprehensive review of Garci and colleagues published in Expert Opinion on Biological Therapy in 2007 examined multiple trials in melanoma, lung cancer, hepatocellular carcinoma, and other malignancies. And the results were mixed. Some trials showed improvement in the immune parameters, increased CD4 in T-cells. improved lymphocyte proliferation responses and some actually showed trends toward improved progression free survival but overall survival benefits were inconsistent and the heterogeneity of the cancer types treatment protocols and outcome measures makes a definitive conclusion difficult as a vaccine adjunct several studies particularly from china have examined ta1 as an adjunct to enhance vaccine responses Dr. Deb Muth 12:11in immune-compromised populations, including the elderly, dialysis patients, and transplant recipients. The rationale is sound. These populations often mount suboptimal antibody responses to vaccines, and TA1’s immune-enhancing effects might improve protection. There are small trials. They have shown improvement in seroconversion rates of hepatitis B vaccines and influenza vaccine in these populations. And though large-scale confirmatory studies are limited, there is a possibility here. Now, on their safety profile, one of the appealing aspects of thymusin alpha-A TA1 is that it’s apparently favorable safety profile in clinical trials. There are some injection site reactions with a little redness, a mild discomfort, and most commonly reported adverse effects. is that their severe adverse events attributable to TA1 have been rare in published trials. However, comprehensive long-term safety data are limited Dr. Deb Muth 13:13And theoretically, concern exists that immune modulation could potentially trigger or exasperate autoimmune conditions in susceptible individuals. Though this hasn’t been clearly demonstrated in clinical trials, integrative medicine considerations for integrative practitioners concerning the thymus and alpha-1, several factors require careful thought. First, sourcing and quality control are critical concerns. Since it’s not FDA approved, TA1 available in the United States typically will come from a compounding pharmacy or an international supplier with variable quality assurance. And pharmaceutical grade product with certificates of analysis showing purity, sterility, and endotoxin testing is essential, but it is readily available from many of these companies. Second, patient selection matters immensely. TA1 should be considered in complex cases where conventional approaches have been insufficient, such as chronic viral infections not responding adequately Dr. Deb Muth 14:21to standard antivirals, post-viral syndromes with evidence of immune dysfunction, cancer patients with immune suppression in consultation with oncology, and it should generally be avoided in active autoimmune disease unless there’s a compelling rationale and close monitoring. Now, TA1 is not a standalone therapy. In cases of chronic viral infection, Comprehensive immune support includes addressing nutritional deficiencies, optimizing vitamin D levels to be between 50 and 80, adequate zinc, selenium, and vitamin A, optimizing gut health since 80% of our immune function is in the gut, you need to optimize gut function. Managing stress from the HPA access dysfunction, chronic cortisol elevation, suppression, and immunity, ensuring adequate sleep, immune memory consolidations during sleep, addressing any metabolic dysfunction, insulin resistance, repairs in the immune function, and the bottom line on thymus and alpha-1 is Dr. Deb Muth 15:26is that it represents legitimate medicine in other countries with a substantial evidence base in specific contexts, but it remains experimental in the U.S., and practitioners using it should provide comprehensive, informed consent about its regulatory status, evidence quality, and source verification. while ensuring it’s part of comprehensive protocols. It is not a magic bullet. And again, what you’re gonna hear me say quite often here is that many of these peptides should be used in conjunction with something else. They should not be used alone. And can peptides be stacked? The answer is yes, they can. So if somebody has an insulin resistance, or a metabolic dysfunction, they can tier TA1 with a GLP-1 like terzepatide or semiglutide. That is not a problem to do that. You need to just work with a practitioner that understands how to do that effectively. So let’s look at BPC-157. Dr. Deb Muth 16:26This is a phenomenon I love BPC-157. Let’s separate it from marketing to actual mechanism of actions here. So BPC-157 stands for Body Protection Compound 157. It is a chain of 15 amino acids that are described as a partial sequence of body protection compound, a protein found in human gastric juice. It has become one of the most hyped peptides in regenerative medicine inside the athletic performance and biohacking communities with claims ranging from healing tendons and ligaments to repairing gut lining or reversing organ damage. The challenge is separating the legitimate mechanisms of science from the marketing hype. The proposed mechanism of BPC-157 are biologically plausible and intriguing. The research suggests that it may influence several growth factor pathways, including vascular endothelial growth factor, VEGF, which promotes new blood vessel formation and has improved better supply of blood flow to injured tissues, theoretically accelerating healing. Dr. Deb Muth 17:40It may also affect fibrous blast growth factor, FGF, and transforming growth factor beta, TGF beta pathways. both involved in tissue repair and remodeling. And some studies actually suggest that BPC-157 modulates inflammatory cascades, potentially reducing excessive inflammation while promoting the resolution phase that allows tissue rebuilding. Now I want to talk just a few moments here about these different tests that we’re talking about tgf beta veg f for those of you who are in our mold world you are very familiar with these uh lab tests we do this to see if you have a mold exposure what’s happening to your body and it’s been very challenging to try to heal this part of the mold illness and manipulate these VEGFs and TGF betas. And so with the fact that BPC helps us modulate this inflammatory cascade, BPC can be very helpful in the world of mold or mycotoxin illness in repairing those parts of the body that have been damaged by the mycotoxins. Dr. Deb Muth 18:48Now there is animal research on BPC-157. It is extensive and primarily from a research group led by pre-drag, oh, I can never say these names, Cyrek at the University of Zagreb in Croatia. Published studies in animal models have shown accelerated healing in a remarkable variety of injury types. A 2011 paper by Chang and colleagues in the Journal of Applied Physiology demonstrated that BPC-157 improved therapy tendon healing in rats with Achilles tendon injuries, and the treated rats showed increased tendon outgrowth, better cell survival in the injured area, enhanced cell migration to the injury site, and improved biochemical strength of the healed tendon compared to controls. Multiple other animal studies have shown similar promising effects. Ligament tears, healing faster in rabbits, muscle damage recovering more quickly in rodent models, gastric ulcers healing in rats given experimental induced ulcerations, inflammatory bowel lesions improving in mouse models of colitis, and even bone to tendon healing showing enhancement in animal studies. Dr. Deb Muth 20:02The breadth of injury types showing benefit in preclinical models explains the enthusiasm of this peptide. However, this is critical. These animal studies, primarily in rodents and rabbits, animal models of injury healing don’t reliably translate to human clinical outcomes. And the doses used in these animal studies when converted to human equivalent doses vary widely. And optimal human dosing is completely unknown at this point. it is all considered experimental and perhaps most importantly there are essentially no peer-reviewed controlled clinical trials in human published in humans published in major medical journals in a 2001 review of arthroscopy and the journal of arthroscopic and related surgery specifically examined in the evidence of bpc 157 and other peptides in musculoskeletal medicine The authors concluded bluntly that BPC-157 lacks evidence from randomized controlled trials and has an unknown safety profile in humans. Dr. Deb Muth 21:09 They emphasized that the jump from animal data to recommending peptides for humans use bypasses the fundamental requirement for Phase I safety studies, Phase II dose-finding studies, and Phase III efficacy trials that would establish whether BPC-157 actually works in humans and whether or not it’s safe. The absence of human safety data is particularly concerning given BPC-157’s proposed mechanisms. Peptides that influence growth factor signaling and angiogenesis could theoretically have off-target effects. Uncontrolled angiogenesis, for instance, is a hallmark of cancer progression. Tumors require blood vessel formation to grow beyond a certain size. And while there’s no evidence that BPC 157 promotes cancer, The complete absence of long term human safety studies means we simply don’t know. This isn’t fear mongering. It’s acknowledging uncertainty and uncertainty exists and understanding that if you’re choosing to use peptides like BPC 157, you are doing it in an experimental model. Dr. Deb Muth 22:17We’re experimenting with the doses that are being used. And there is potential for it to cause cancer cells in your body to grow. And you need to be aware of this and understand the risks that you’re taking when you’re using an investigational or off label use peptide. Now, quality control issues with BPC also exist. It’s not FDA approved for any indication in the US. It’s not approved in any major regulatory jurisdiction worldwide. It’s marketed as a research chemical explicitly to bypass FDA oversight. And commercial sources selling BPC-157 range from compounding pharmacies, which have some quality standards but are not FDA inspected. You can take that for what you want to believe on that one. to overseas suppliers operating with absolutely no quality assurance whatsoever. If you are choosing to use BPC-157, you have to understand who’s manufacturing it for you, where you are getting it from, how pure it is. Dr. Deb Muth 23:26You want to make sure that you have the certificate of analysis and that it does not contain bacterial endotoxins that can contaminate the peptide or degrade the peptide and cause other issues for you. So when you talk about peptides with patients regarding BPC-157 or if you’re listening to this and you’re already using BPC-157 or other peptides, that are quote-unquote not for human consumption, an evidence-based response acknowledges both the appeal and the limitations. And you want to talk about the animal data that’s definitely showing some progress and some potential, but we don’t know what we don’t know in humans. If people are willing to take that risk, that is up to them to do that. But using BPC right now is experimental and people need to be aware of that. Are there evidence-based alternatives for patients with tendon or ligament injuries? Dr. Deb Muth 24:26And there are. There’s PRP, which has been studied in multiple randomized controlled trials. for conditions like lateral epicondylitis, tennis elbow, Achilles issues, patellar issues, knee issues. However, I want to caution you on this too. So the study that was done by Cox and colleagues in muscles, ligaments, and tendons in the Journal of 2014 showed modest benefits in pain and function compared to controls. And though the effects vary by injury type, PRP preparations can be helpful. You have to understand that a lot of times when people are doing PRP injections in their office, they are not doing it exactly the same way it was done in the study. And not to mention, if you’re using your own PRP to heal a ligament or a tendon or help your arthritis and you’re 60 or 70 years old, That is not good quality protein rich plasma. It is old protein rich plasma. And you’re not going to see necessarily the same benefits that you would see if you were using placental tissue or umbilical tissue. Dr. Deb Muth 25:33You also want to address the nutritional deficiencies or support that’s needed for connective tissue healing. And these are collagen peptides dosed at 15 grams a day. And this has been shown in a study by Shaw and colleagues in the American Journal of Clinical Nutrition in 2017 to augment collagen synthesis when combined with intermittent loading. Vitamin C is also an essential cofactor for collagen production and stabilization of collagen structure at a dose of around 500 to 1000 milligrams a day to support this process. You also need to have good adequate intake of copper and zinc. These are cofactors in collagen. Silica is also important. This comes from horsetail extract. This provides additional support as well. So more importantly, I think remembering that rehabilitation matters as well. Doing these protocols without doing some rehab is not going to get you where you want to go. Dr. Deb Muth 26:33There’s a research study by Alfredson and others for Achilles tendinopathy using the control lengthening of muscle tendon units under load to promote tendon remodeling and healing. These protocols have solid evidence and cost nothing beyond professional guidance from a physical therapist. They are important for patients seeking cutting edge regenerative approaches. Stem cell therapies, growth factors, concentrates derived from patients’ own tissues like PRP. These have a lot of good endogenous materials and they have good safety profiles. BPC-157 represents the perfect example of how promising Preclinical science gets marketed far beyond the evidence and it may eventually prove to be valuable. I think it will. But right now that determination does require some human studies and hopefully with the administration that we have right now and Bobby Kennedy, we will actually start to see some of that occur. Now the next peptide I want to talk about is TB4, thymus and beta-4. Dr. Deb Muth 27:36This is a wound healing peptide. It is a 43 amino acid peptide that’s naturally present in virtually all human cells except red blood cells. It’s actually one of the most abundant peptides in the human body, particularly concentrated in blood platelets, wound fluid, and many tissues. It’s naturally ubiquity makes it mechanistically interesting. The body wouldn’t produce it in such abundance if it didn’t serve a function. So the primary role of TB4 involves building G-actin. It’s a form of monomeric actin. And it’s structural protein that forms the microfilaments within the cells, providing cellular structure and enabling cell movement. TB4 prevents from F-actin filaments. I’m not going to talk too much about this. It’s really critical for wound healing as cells need to migrate into the injury sites. Dr. Deb Muth 28:37so the cell shape changes and the cellular response to the injury. So think of this as though you tore your meniscus and the body created all this TB4 to come to that injury to try to heal that site. That’s exactly what the TB4 is doing inside the body when there’s an injury. It’s been shown in research to help produce new blood vessel formation, promote endothelial cells, It helps modulate inflammatory cytokines, potentially reducing TNF-alpha, IL-1, and possibly protecting in programmed cell death, which we call apoptosis. And some studies suggest that it is cardioprotective in its effects in animal models of myocardial infarction, so heart attack, and neuroprotective in other models for brain injury. Now, these remain to be preliminary, but they are being seen. So the regulatory status on TB4 can create some confusion. Dr. Deb Muth 29:40The natural TB4 molecule itself is not FDA approved as a drug. However, TB4 based drug candidates called RGN259, formerly TB4, has been in the development by regen tree for corneal injuries of the dry eye disease. And as of recent updates, this drug is completed phase three trials for its neurotrophic keratopathy, severe corneal condition. But the FDA approval is still pending. So that means that the most advanced TB4-based pharmaceuticals hasn’t yet crossed the finish line for approval. The commercial peptide market further muddies the picture with TB500, which is often described as the synthetic fragment of TB4. However, this extract’s relationship between TB500 and TB4 varies depending on the source. Dr. Deb Muth 30:41So some claim that TB500 is identical to TB4, but positions 1 through 4 suggest it’s a different fragment. and the quality control across suppliers is not existent. So this confusion is part of why recommending TB500 becomes problematic for practitioners and patients, often because they aren’t certain what molecule they’re actually getting. The evidence base for TB4 in humans is limited, primarily to eye research, and the studies from Sohn’s and colleagues published in journals like Vitamins and Hormones in 2016 have examined topical TB4 for corneal injuries and neurotrophic keratopathy, dry eye, and other surface diseases. Now, these studies showed some promise in promoting this, and there is, however, a topical application to the cornea that is vastly different from a systemic injection. So for systemic use in wound healing, musculoskeletal issues, Dr. Deb Muth 31:42cardiac protection, neuroprotection, human clinical trials. There is scarce to non-existent evidence in humans. Most of the evidence remains in animal models or cell culture studies. And a review by Flip and colleagues in the Journal of Investigational Dermatology in 2006 detailed TB4’s effects on the matrix remodeling during wound repair in animal models, showing effects on collagen disposition, granulation, tissue reformation, and wound contraction. Another review by Ho and colleagues in expert opinion on biological therapy in 2007 discussed TB4’s potential in tissue regeneration and regenerative medicine, but noted the field remained largely blank. preclinical. So this is really important again to understand that there is just not enough human data. So there is a concern with cell division and migration. This theoretically exists Dr. Deb Muth 32:45for the potential effects on cancer cells, which would also rely on migration and division and other intended consequences of disrupting normal cellular architecture. These aren’t proven risks, but they are unexplored questions that we need to be aware of when we’re using peptides. This can cause cancerous tissue to grow. Very similar to what we talked about with BPC-157. These are also sold as research chemicals. There is no FDA oversight. So purity, potency, contaminations all still exist for these peptides. Now from an integrative perspective, the natural presence of TB4 in wound fluid and its biological roles in healing are legitimate science. in presence does not equal therapeutic utility. The body tightly regulates where and when and how much TB4 is present through natural production and bypassing that regulation with external dosing may or may not cause us to have beneficial or introduce risk. Dr. Deb Muth 33:49So we need to know that this is experimental use. Those people who are seeking wound healing and tissue repair the evidence-based approach of the body’s own capacity to heal is huge definitely want to be increasing your protein intake optimizing your zinc copper vitamin c and vitamin a and then managing glucose is really important during this time as well so let’s talk about a fun topic now and that’s growth hormone secretagogues this is the anti-aging hype machine these peptides in this category are things like semoralin ipameralin cjc 1220 1295 and others and among the most aggressively marketed in anti-aging and longevity medicine they all share a common goal stimulating the pituitary gland to release more growth hormone and the appeal is understandable. GH levels decline with age, and this decline is associated with increased fat mass, decreased lean muscle, reduced bone density, and other aspects of aging. Dr. Deb Muth 34:55The other times we’ll see growth hormone levels decline significantly is with chronic illness, and the logic is to restore youthful GH levels and youthful physiology. Now, semirelin from an FDA approved diagnostic to compound anti-aging product. Semirelin is a 29 amino acid peptide representing the first 29 amino acids of the full 44 amino acid human growth releasing hormone, GHRH. We talked about this on another episode of the podcast. And you can go back and listen to that one a little bit if you want. This fragment contains the complete biological activity of the full GHRH molecule and it binds to GHRH receptors in the anterior pituitary and stimulates growth releasing peptides, growth hormone releasing peptides. Semirelin was previously FDA approved as diagnostic testing of growth hormone secretion, essentially, to determine if the pituitary could still respond to GHRH stimulation in patients being evaluated for growth hormone deficiency. Dr. Deb Muth 36:06However, the manufacturer was discontinued and there was no longer an FDA approved semirelin product on the market in the United States. What exists now is semirelin available from compounding pharmacies used off label for anti-aging, body composition, and general growth hormone optimization purposes. This represents a significant gray area. Again, compounding medications serve a very important role, but they need to meet certain recommendations and regulations, as we’ve talked about in the past. You want to make sure that your compounding pharmacy that you’re obtaining semirelin from is qualified to do that, that they are doing best practices, and that you’re getting a good product. The theoretical advantage to semirelin over direct growth hormone administration is that it preserves more of the physiological growth hormone secretion patterns. Natural GH is released in pulses, primarily during sleep, not as a continuous elevation. Dr. Deb Muth 37:07So semirelin stimulates the pulses rather than providing a constant super physiological growth hormone level. And that pulsatile pattern is thought to reduce some of the side effects and metabolic concerns that we have with continuous growth hormone exposure. However, the evidence supporting semirelin for anti-aging and body composition in healthy adults is minimal. Most of the data comes from studies conducted in the 1990s when the FDA approved product existed. Not that that means it’s bad. We have drugs that have been in the market for over a hundred years that are still there, that still have the research and are still being used successfully and safely today. So we don’t want to let that really make us think that this product isn’t safe. So a 2006 review from Walker in Clinical Interventions of Aging suggested that semirelin might be a better approach than direct GH for adult onset growth hormone insufficiency, but they do acknowledge that the evidence was limited. Dr. Deb Muth 38:12And although we don’t have any large scale trials that we can examine for semirelin’s efficacy, it is now commonly prescribed. And the optimal dosing for anti-aging purposes is still unknown. It is considered experimental and it does vary from person to person, but it is still unstudied. The effects on cancer risk, cardiovascular disease, metabolic dysfunction over long time periods are also still unknown. I would argue that the side effects or the risk factors of not having growth hormone are equally as bad as the unknowns that we have here. We’re not looking to try to get super physiological doses. We’re trying to restore youthful GH levels. Typically, we’re not trying to restore back to a 20-year-old. We’re trying to restore back maybe 10 years. That is a better way of doing this. And I think that’s important for people to understand. Now, ipamirelin is the ghrelin mimicker. Dr. Deb Muth 39:12Ipamirelin is a pent-up peptide, five amino acid, that acts as a growth hormone secretagogue receptor, a GHS-R agonist. It mimics the action of ghrelin, the hunger hormone, that also stimulates growth hormone release. The proposed advantage over earlier secretagogues is that ipamirelin stimulates growth hormone release without significantly affecting cortisol, prolactin, or other glucose things, which can be increased by growth hormone secretagogues. The regulatory status is clear. Ipamirelin is not FDA approved for any indication. It’s sold as a research chemical. Human evidence is thin. It’s limited to single dose studies examining how quickly it’s absorbed and metabolized with minimal data on dosing and clinical outcomes. Now there are marketing claims for ipamirelin and they are extensive. Dr. Deb Muth 40:13It increases lean muscle mass, it decreases body fat, it improves sleep quality, faster recovery from workouts, enhanced injury healing, better skin quality. The evidence supporting these claims in humans is not available we don’t have it these are claims that are made by the effects that we know from growth hormone so it’s not necessarily a bad thing we know what growth hormone does we know growth hormone does all of these things if ipamorelin is a precursor to that it will obviously help improve those things making that correlation of what growth hormone does So there are safety concerns that mirror the same as any other growth hormone elevating therapy. It can cause fluid retention, joint pain, carpal tunnel syndrome, insulin resistance, glucose intolerance, and theoretically, can it increase calcium? cancer risks? It can because IGF-1 promotes cell proliferation and can inhibit apoptosis in cancer cells. Now remember, your body makes IGF-1. Dr. Deb Muth 41:15If it’s not making enough of it, that’s a problem. If it’s making too much of it, That’s a problem. So just understand that if you are adding these things, and especially in elevated doses, you are taking a potential risk. So there is also now CJC 1295 is a modified GHRH analog of 30 amino acid peptide based on GHRH structure, but with modifications. So it includes the addition of drug affinity complex, DACC, DAC, which involves conjugation with a small albumin binding molecule, dramatically extends the peptide’s half-life from minutes to as much as potentially a week or more. And this creates sustained growth hormone elevation rather than that pulsatile release. There are actually two versions of this. There’s CJC 1295 with DAC, longer acting version, and CJC 1295 without DAC, which is essentially a shorter duration of semirelin. Dr. Deb Muth 42:19And so when we’re comparing products, it is… only the difference between long acting and short acting. The human evidence for CJC 1295 is limited to a single published phase one study by Techman and colleagues in the Journal of Clinical Nutrition and Metabolism in 2006. And the study involves 18 healthy young adults showed that CJC 1295 with DAC produced a sustained elevation of GH and IGF-1 lasting several days after the injection. That’s essentially the entire published human evidence of this peptide. There are no phase two studies examining optimal dose. So that is all considered experimental. And there is no phase three studies examining clinical efficacy. So the sustained GH levels created by CJC 1295 with DAC raises specific concerns because the natural GH secretion It goes up and down, up and down, up and down. Dr. Deb Muth 43:19And that constant elevation may have a different metabolic and cellular effect. And we just really don’t know what that’s going to be yet. So we can understand that elevated IGF-1 levels can theoretically increase cancer concerns and metabolic risks. So rather than always injecting peptides, which are very expensive… You can do other things. And there was a study by Hartman and colleagues in the Journal of Clinical Endocrinology and Metabolism in 1992 that demonstrated the 48-hour fast increased integrated growth hormone secretion five-fold through increased GH levels. Now, the problem with this is fasting for 48 hours is a challenge. And how long is it going to increase the growth hormone secretion without causing issues? Or in general, how long is it going to go up? Dr. Deb Muth 44:19So we have to be cautious about that as well. Sleep optimization is non-negotiable. The majority of growth hormone secretion occurs during sleep, slow wave sleep, typically the first sleep cycle, and poor sleep quality or insufficient sleep typically. can dramatically affect your growth hormone levels. And then high intensity interval training, HIIT resistance training can stimulate growth hormone as well. This was seen in a study by Godfrey and colleagues in sports medicine in 2003 and was examined in exercise-induced growth hormone responses to athletes. So we definitely see these kinds of things. So let’s talk about some longevity peptides now. These expand the telomere. So there’s epitalin and epithalamin and when these are used in anti-aging they can produce some amazing results. Dr. Deb Muth 45:22So epitalin is a synthetic terapeptide, just four amino acids. It was originally synthesized as a simplified version of epithalamine. a pineal gland extract containing multiple peptides. The synthetic four amino acid version was created to isolate what researchers believed might be the active anti-aging component. The mechanism produced for epitalin centers on telomere and telomerase, Telomeres are protective caps at the end of the chromosomes consisting of repetitive DNA sequencing. And every time a cell divides, telomeres shorten slightly because DNA polymers cannot fully replicate the ends of the linear chromosomes. So this progressive shortening acts as a molecular clock. After 50 or 70 divisions, the telomeres become critically short, triggering a cellular senescence. Dr. Deb Muth 46:22This telomere shortening is one mechanism of cellular aging and telomeres in the enzyme that can rebuild telomeres by adding these caps back onto the end of the chromosome. It’s active in stem cells, germ cells, and unfortunately in about 85 to 90% of the cancer cells. In most adult somatic cells, telomerase is inactive or present at very low levels, allowing the telomeres to shorten with division. The research on epitalin suggests it might activate this telomeres act telomeres process primarily from a research group led by Vladimir in Russia. Vladimir Kavasan in Russia. He is a huge peptide researcher or was he passed away with publications dating back to the early 2000s and a study published in bio gerontology in 2000 by Kavasan Dr. Deb Muth 47:25and colleagues examined the effect of epitalin on the lifespan of fruit flies, and they treated fruit flies that showed a modest increase in mean and maximum lifespan compared to its controls by approximately 10 to 15% lifespan extension in some experimental groups. And there were other studies in 2003 that examined epitalamine in a female Swiss-derived mouse. This was done by Ann Simove and colleagues. And the researchers reported that epitalin treatment was associated with increased lifespan as well. And the most cited mechanistic work comes from cell culture studies. And that is also Cavason’s group that published this research in 2003, showing increased telomeres activity in cultured somatic cells again. More recently, between 20 and 25, the series of publications have continued to explore epithelial effects on telomere dynamics in cell cultures. Dr. Deb Muth 48:32So there is a lot of research that’s been done. The mass majority has been done on epithelin. And most of it has been done by a single research group in Russia. There is some restrictions on some of the cell culture data that we’re seeing. And it does show that epithelin sometimes can be described as a regulating hormone. Carcadian rhythm for melatonin production, which is derived by the penile extracts. And however the evidence for this affects minimally and mechanistically unclear, the pineal gland primarily functions as melatonin secretion in that light-dark cycles. So Epithalin or epitalin is not FDA approved. It is not approved for any major regulatory jurisdiction. It is sold as a research chemical only. Dr. Deb Muth 49:33So you need to follow the same safety profiles that we’ve talked about in other episodes and in today’s episodes. And when we’re talking about epithalin, and we’re excited about it being an anti-aging science, we should balance this with the honesty and the evidence of the quality of that evidence. We don’t know its safety effect. We don’t know if it’s going to increase the risk of cancer. We can’t verify that. And we need to be using it in an experimental use of unknown risks only. Of course, diet, physical activity, stress management, sleep quality, all of those things are important for us to be looking at when we’re looking at these peptides. Now, I want to get into some of the brain peptides. This is the nootrophic frontier. C-Max and C-Lank, there is Russian pharmacology that’s done. C-Max and C-Lank represent an interesting case study in how different regulatory environments and research traditions Dr. Deb Muth 50:36create challenges in evaluating this evidence. Both peptides were developed in Russia, are approved for their specific indications and have substantial Russian language and literature supporting their use. However, the FDA approval in the United States is still not there. C-Max is a seven amino acid. It’s a synthetic analog. It is a fragment, particularly ACTH 4 through 10. It’s sometimes called the melanocortin effects because it involves the melanocortin receptors of the central nervous system. CMAX was developed by the Institute of Molecular Genetics of Russia Academy of Sciences and is approved in Russia for several indications, including acute stroke, transient ischemic attacks, cognitive disorders. It has Russian approval and is based on clinical trials primarily in Russia. Dr. Deb Muth 51:39It does help to increase brain-derived neurotrophic factor, BDNF, a protein critical for neuroplasticity, the brain’s ability to form new connections and adapt to the challenges. BDNF supports neuronal survival and promotes growth of these new neurons. C-Max also influences neurotransmitter systems, particularly dopamine and serotonin, and there is some research that suggests it affects on metabolism as well, and endogenous opioid peptides that involve pain reception and mood regulation. So it has some good potentials there. There is also C-Link, which is a hepatopeptide structurally similar to Tufts’ and an immune modulatory peptide. It was also developed in Russia and was approved for anxiety disorders as a neurotropic. Its effects involve anxiolytic effects, possibly through the GABAnergic system or the GABA system of the brain, and immune modulation. Dr. Deb Muth 52:44The Russian research is examined by C-Link for anxiety disorders. and finding reductions in anxiety without sedation. There is a dependency potential or cognitive impairment does not exist like it does with benzodiazepines with C-Link. So that is really good. And they do report attention and memory improvement using C-Link. There is a study that was done in neuroscience and behavioral psychology in 2018 that examined C-Linx effects and proposed that it exerts cytoprotective effects through BDNF pathways similar to C-Max. So both of these are Russian research-based They’re not wrong or fraudulent. It’s just that they are from Russia and we all have our concerns with Russia. However, that does not necessarily mean their research doesn’t hold quality. Dr. Deb Muth 53:49Neither peptide is approved by the FDA, and so you are using this off-label. The same rules apply for all of the other peptides that we’ve talked about that are produced off label. You want to do the same things that you would do with anything else. Good protein, omegas, B vitamins, acetylcarnitine, exercise, sleep, all of that still applies when we’re using these peptides. So I want to talk briefly about clinical decision and framework when we’re looking at this. First and foremost, we always want to go to FDA-approved peptides. Secondly, we would look at international approval with peptides that are established in other countries but lack FDA approval. And then preclinical evidence only or experimental peptides. These can be used, but they are not ethically recommended in the traditional medicine world. Dr. Deb Muth 54:50 If patients use them, we need to have appropriate counseling about the evidence surrounding them, the safety, and where to find them. how to find them and how to ask for these certificates of analysis. So I think it’s really good that we were exploring all these peptides and understanding what they are. There’s a lot of controversy out there. There’s a lot of concern out there. And what we can say with confidence is that peptides are powerful biological signaling molecules. Some peptide based medications, semi-glutide, triseptide, PT 141, Lupron that are all FDA approved. can dramatically improve outcomes in patients that are obviously selected for the correct ones. There are many other peptides that we address that are integrative and longevity space in the regenerative medicine. These peptides are all experimental. That does not automatically make them wrong. Dr. Deb Muth 55:50It just means that we need to be honest about what we’re doing with them and we need to be cautious with the patients so that they can make a decision to be part of an experimental study. in looking at how to use these peptides. So peptides are tools like any other tools. They work best in the hands of skilled people, and they are applied to appropriate situations, integrating into comprehensive approaches that address root causes. The most powerful peptide administered to a patient with untreated inflammation, hormonal chaos, nutritional deficiencies, and disorders of sleep will disappoint. The simplest evidence-based interventions apply. to a patient whose foundational physiology has been optimized. And this is the art of the science of peptide, right? If done right, respecting both the power of these molecules and the complexity of human beings that we are privileged to serve can make a difference in their lives. So thank you for listening to this episode. Dr. Deb Muth 56:52I hope this was helpful. If you can know of somebody that might benefit from this, please like, share, and subscribe. It means a lot to us. And I hope you join us for our next episode of Let’s Talk Wellness Now. Welcome to Let’s Talk Wellness Now, where we bring expert insights directly to you. Please note that the views and information shared by our guests are their own and do not necessarily reflect those of Let’s Talk Wellness Now, its management, or our partners. Each affiliate, sponsor, and partner is an independent entity with its own perspectives. Today’s content is provided for informational and educational purposes only and should not be considered specific advice, whether financial, medical, or legal. While we strive to present accurate and useful information, we cannot guarantee its completeness or relevance to your unique circumstances. We encourage you to consult with a qualified professional to address your individual needs. Dr. Deb Muth 57:54Your use of information from this broadcast is entirely at your own risk. By continuing to listen, you agree to indemnify and hold Let’s Talk Wellness Now and its associates harmless from any claims or damages arising from the use of this content. We may update this disclaimer at any time and changes will take effect immediately upon posting or broadcast. Thank you for tuning in. We hope you find this episode both insightful and thought-provoking. Listener discretion is advised.The post Episode 258 – Investigational Peptides: What's Promising, What's Hype & What You Must Know first appeared on Let's Talk Wellness Now.

Tufts, Gayle www.deutschlandfunkkultur.de, Politisches Feuilleton

The roads to Fort Wayne and Salem are complete. The teams now have to hit the roads to get there physically. Which women's team comes out the champs? Which men's teams survive to play for a national title? 2, 4, 6, 8, who do we appreciate? Those numbers will used this coming week as we work our way down from quarterfinals and semifinals. On Mondays' super-sized edition of Hoopsville, we show our appreciation for the programs still playing in the DIII national tournaments. We chat to all four of the women's programs still dancing and showcase a number of the men's teams that will lace it up on Thursday. Who might be best prepared as the national spotlight gets brighter for all? Guests appearing on the Hudl Hoopsville Hotline in Part 1: - Jackson Niego & Ron Rose - No. 8 Illinois Wesleyan junior guard & men's coach - Brandon Linton - No. 12 Tufts men's coach - Nick Buffalo & Anthony Medina - No. 3 St. Thomas junior forward & men's coach - Brooke Batchelor, Meg Barber, & Caroline Peper - UAA Defensive Player of the Year, No. 1 NYU women's coach, & UAA Player of the Year Hoopsville is presented by D3hoops.com from the WBCA Studios.

Dr. Allen Taylor spent 40 years at Tufts discovering how diet affects vision. Learn why high glycemic foods accelerate macular degeneration and cataracts—and what you can do to protect your eyes.Dr. Allen Taylor directed the Laboratory for Nutrition and Vision Research at Tufts University for four decades, pioneering groundbreaking discoveries about how nutrition impacts age-related eye diseases. In this comprehensive interview, he reveals how high glycemic diets create a "double jeopardy" in your eyes—damaging proteins while simultaneously destroying your cellular cleanup systems.Dr. Taylor explains the cellular mechanisms behind age-related macular degeneration (AMD) and cataracts, breaking down complex biochemistry into actionable insights. You'll learn about the epidemiological evidence linking Western diets to AMD risk, why blood sugar spikes matter even for non-diabetics, and how advanced glycation end products (AGEs) accumulate in retinal tissue.The conversation covers practical strategies including which antioxidants matter most (vitamin C, vitamin E, lutein), why omega-3 fatty acids support retinal health, and how switching from high to low glycemic foods could prevent 100,000 cases of blinding AMD annually. Dr. Taylor also discusses his current intervention trial testing whether people with early AMD can preserve vision through dietary changes.Key topics: macular degeneration, cataracts, glycemic index, nutrition and vision, eye health, aging, preventive medicine, antioxidants, drusen, photoreceptor health, retinal pigment epithelium, and practical dietary interventions for longevity

In this throwback episode, host Shikha Jain, MD, speaks with Don Dizon, MD, about innovation throughout times of uncertainty in medicine, challenges currently facing physicians and more. ·       Welcome to another exciting episode of Oncology Overdrive 0:15 ·       About Dizon 0:25 ·       The interview 1:08 ·       How did you decide to become an oncologist and navigate a traditional academic career with many non-traditional "add-ons"? 1:46 ·       Jain and Dizon on the importance of providing humanity to physicians. 5:40 ·       Jain and Dizon on finding balance when providing patients with information.  7:45 ·       Jain and Dizon on federal funding challenges facing oncology advancements.  8:39 ·       Can you tell us more about transitioning to your new role at Tufts? 11:43 ·       Jain and Dizon on the growing amount of career shifts in medicine. 15:35 ·       How do we move forward with these new guardrails up from corporatization? 17:15 ·       Jain and Dizon on how the age of social media has changed the perception, training and demands of doctors. 22:39 ·       Dizon and Jain on the power of being able to admit "I don't know." 25:52 ·       What are some tips that you have for new attendings and people just starting in their careers? 31:13 ·       Dizon and Jain on the importance of humanizing patients during their care. 38:15 ·       If someone could only listen to the last few minutes of this episode, what would you want listeners to take away? 41:52 ·       How to contact Dizon 42:32 ·       Thanks for listening 43:26 Don Dizon, MD, is a professor of medicine at Tufts University and is the system chief of hematology and oncology for Tufts Medicine. He is also the editor in chief of CA: A Cancer Journal for Clinicians, the flagship journal of the American Cancer Society as well as the vice-chair of membership and accrual at the SWOG Cancer Research Network. We'd love to hear from you! Send your comments/questions to Dr. Jain at oncologyoverdrive@healio.com. Follow Healio on X and LinkedIn: @HemOncToday and https://www.linkedin.com/company/hemonctoday/. Follow Dr. Jain on X: @ShikhaJainMD. Dizon can be reached on Tiktok @drdonsdizon, Instagram @drdonsdizon and LinkedIn. Disclosures: Jain and Dizon report no relevant financial disclosures.

What if cancer isn't just a disease… but a split personality inside your own body? In this episode of Mayim Bialik's Breakdown, Dr. Michael Levin (Professor of Biology at Tufts University, Director of the Allen Discovery Center) drops paradigm-shattering insights that could redefine medicine, consciousness, intelligence...and what it even means to be human. He explains why he calls cancer “dissociative identity disorder of the body” — a breakdown in the body's bioelectrical network — and how this could open the door to treating cancer without drugs or chemotherapy, why “mind blindness” prevents us from recognizing nonhuman intelligence, and how “human” might be defined in a future of tech implants and biological augmentation. Dr. Levin also breaks down: - What does a body think about before there is a brain? - Can we regrow limbs in our lifetime? - Are we closer than we think to communicating with our organs via an app? - What flatworms reveal about how trauma and memory are imprinted in tissue, and whether we might one day overwrite trauma itself - What nonhuman intelligence could actually look like - How you might play tic-tac-toe with an alien - Real dangers of anthropomorphizing AI Dr. Levin also tackles some of humanity's biggest existential questions: - Are we defining consciousness all wrong? - How can ancient traditions and modern biophysics coexist? - Why compassion may be the most advanced technology we have From developmental biophysics to computer science to cognitive science, this conversation explores how intelligence may be woven into life itself — from cells to organs to entire bodies. If what he's saying is right… Medicine will change. AI debates will change. And our understanding of ourselves will change. You will never look at your body the same way again! Learn more about Dr. Michael Levin and his work: ⁠https://drmichaellevin.org/⁠ ⁠https://thoughtforms.life/⁠ ⁠https://www.youtube.com/@drmichaellevin/playlists⁠ Follow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if cancer isn't just a disease… but a split personality inside your own body? In this episode of Mayim Bialik's Breakdown, Dr. Michael Levin (Professor of Biology at Tufts University, Director of the Allen Discovery Center) drops paradigm-shattering insights that could redefine medicine, consciousness, intelligence...and what it even means to be human. He explains why he calls cancer “dissociative identity disorder of the body” — a breakdown in the body's bioelectrical network — and how this could open the door to treating cancer without drugs or chemotherapy, why “mind blindness” prevents us from recognizing nonhuman intelligence, and how “human” might be defined in a future of tech implants and biological augmentation. Dr. Levin also breaks down: - What does a body think about before there is a brain? - Can we regrow limbs in our lifetime? - Are we closer than we think to communicating with our organs via an app? - What flatworms reveal about how trauma and memory are imprinted in tissue, and whether we might one day overwrite trauma itself - What nonhuman intelligence could actually look like - How you might play tic-tac-toe with an alien - Real dangers of anthropomorphizing AI Dr. Levin also tackles some of humanity's biggest existential questions: - Are we defining consciousness all wrong? - How can ancient traditions and modern biophysics coexist? - Why compassion may be the most advanced technology we have From developmental biophysics to computer science to cognitive science, this conversation explores how intelligence may be woven into life itself — from cells to organs to entire bodies. If what he's saying is right… Medicine will change. AI debates will change. And our understanding of ourselves will change. You will never look at your body the same way again! Learn more about Dr. Michael Levin and his work: ⁠https://drmichaellevin.org/⁠ ⁠https://thoughtforms.life/⁠ ⁠https://www.youtube.com/@drmichaellevin/playlists⁠ Follow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

What if cancer isn't just a disease… but a split personality inside your own body? In this episode of Mayim Bialik's Breakdown, Dr. Michael Levin (Professor of Biology at Tufts University, Director of the Allen Discovery Center) drops paradigm-shattering insights that could redefine medicine, consciousness, intelligence...and what it even means to be human. He explains why he calls cancer “dissociative identity disorder of the body” — a breakdown in the body's bioelectrical network — and how this could open the door to treating cancer without drugs or chemotherapy, why “mind blindness” prevents us from recognizing nonhuman intelligence, and how “human” might be defined in a future of tech implants and biological augmentation. Dr. Levin also breaks down: - What does a body think about before there is a brain? - Can we regrow limbs in our lifetime? - Are we closer than we think to communicating with our organs via an app? - What flatworms reveal about how trauma and memory are imprinted in tissue, and whether we might one day overwrite trauma itself - What nonhuman intelligence could actually look like - How you might play tic-tac-toe with an alien - Real dangers of anthropomorphizing AI Dr. Levin also tackles some of humanity's biggest existential questions: - Are we defining consciousness all wrong? - How can ancient traditions and modern biophysics coexist? - Why compassion may be the most advanced technology we have From developmental biophysics to computer science to cognitive science, this conversation explores how intelligence may be woven into life itself — from cells to organs to entire bodies. If what he's saying is right… Medicine will change. AI debates will change. And our understanding of ourselves will change. You will never look at your body the same way again! Go to helixsleep.com/breakdown for 27% off sitewide. For an exclusive offer, go to https://bioptimizers.com/breaker and use my exclusive code BREAKER for 15% off. If you're struggling with OCD or unrelenting intrusive thoughts, NOCD can help. Book a free 15 minute call to get started: https://learn.nocd.com/BREAK Get 15% off OneSkin with the code BREAK at https://www.oneskin.co/BREAK #oneskinpod Head to Superpower.com and use code BREAK at checkout for $20 off your membership. Live up to your 100-Year potential. #superpowerpod Learn more about Dr. Michael Levin and his work: https://drmichaellevin.org/ https://thoughtforms.life/ https://www.youtube.com/@drmichaellevin/playlists Follow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoicesSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What if cancer isn't just a disease… but a split personality inside your own body? In this episode of Mayim Bialik's Breakdown, Dr. Michael Levin (Professor of Biology at Tufts University, Director of the Allen Discovery Center) drops paradigm-shattering insights that could redefine medicine, consciousness, intelligence...and what it even means to be human. He explains why he calls cancer “dissociative identity disorder of the body” — a breakdown in the body's bioelectrical network — and how this could open the door to treating cancer without drugs or chemotherapy, why “mind blindness” prevents us from recognizing nonhuman intelligence, and how “human” might be defined in a future of tech implants and biological augmentation. Dr. Levin also breaks down: - What does a body think about before there is a brain? - Can we regrow limbs in our lifetime? - Are we closer than we think to communicating with our organs via an app? - What flatworms reveal about how trauma and memory are imprinted in tissue, and whether we might one day overwrite trauma itself - What nonhuman intelligence could actually look like - How you might play tic-tac-toe with an alien - Real dangers of anthropomorphizing AI Dr. Levin also tackles some of humanity's biggest existential questions: - Are we defining consciousness all wrong? - How can ancient traditions and modern biophysics coexist? - Why compassion may be the most advanced technology we have From developmental biophysics to computer science to cognitive science, this conversation explores how intelligence may be woven into life itself — from cells to organs to entire bodies. If what he's saying is right… Medicine will change. AI debates will change. And our understanding of ourselves will change. You will never look at your body the same way again! Go to helixsleep.com/breakdown for 27% off sitewide. For an exclusive offer, go to https://bioptimizers.com/breaker and use my exclusive code BREAKER for 15% off. If you're struggling with OCD or unrelenting intrusive thoughts, NOCD can help. Book a free 15 minute call to get started: https://learn.nocd.com/BREAK Get 15% off OneSkin with the code BREAK at https://www.oneskin.co/BREAK #oneskinpod Head to Superpower.com and use code BREAK at checkout for $20 off your membership. Live up to your 100-Year potential. #superpowerpod Learn more about Dr. Michael Levin and his work: https://drmichaellevin.org/ https://thoughtforms.life/ https://www.youtube.com/@drmichaellevin/playlists Follow us on Substack for Exclusive Bonus Content: ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠https://bialikbreakdown.substack.com/⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠BialikBreakdown.com⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠YouTube.com/mayimbialik⁠⁠⁠ Learn more about your ad choices. Visit megaphone.fm/adchoices

3-4-26 Full Show - Patriots announce the release of Stefon Diggs / Jayson Tatum return appears to be growing closer by the day full 9981 Wed, 04 Mar 2026 23:22:20 +0000 iDqd3buK0Tg8lkQeWX0CNFDE5exzM1vr sports WEEI Afternoons sports 3-4-26 Full Show - Patriots announce the release of Stefon Diggs / Jayson Tatum return appears to be growing closer by the day WEEI Afternoons is high-energy Boston sports talk built for passionate fans who want lively debate and real-time reaction. Featuring hosts Andy Hart, Nick “Fitzy” Stevens and former Patriots linebacker Ted Johnson, the show delivers bold opinions, strong chemistry and unfiltered takes on the biggest moments in New England sports. From breaking down Patriots game plans and reacting to Red Sox developments, to Celtics momentum, Bruins insights and the biggest NFL and MLB storylines of the week, WEEI Afternoons offers lively analysis, candid debate and real-time takeaways for Boston sports fans. Fast-moving, entertaining and deeply connected to Boston sports culture, WEEI Afternoons is where the city's conversations come to life. Hart, a Tufts graduate, joined WEEI in 2019 after nearly two decades at Patriots.com. With WEEI he has served as the station's Patriots reporter, columnist, and co-host of the national ‘6 Rings & Football Things' podcast. Stevens is a Massachusetts native with a passion for Boston sports. He joined WEEI in the summer of 2019 and has hosted shows across every daypart at the station, including “The 6 Rings Postgame Show” with Hart after every Patriots game. Johnson joined WEEI after serving as an on-air host for The Sports Hub since 2018. Upon his retirement from the NFL in 2005, he began his professional media career at CBS Boston doing pre- and postgame shows for the Patriots. © 2026 Audacy, Inc. ee8a5140-004d-11f1-90f4-4db661719af0 Sports Fa

Send a textDr. Barbara Kellerman is a Fellow at the Harvard Kennedy School's Center for Public Leadership. She was the Founding Executive Director of the Center, and a member of the Kennedy School faculty for over twenty years. Kellerman has held professorships at Fordham, Tufts, Fairleigh Dickinson, George Washington, Christopher Newport, and the Tuck School of Business at Dartmouth. She also served as Director of the Center for the Advanced Study of Leadership at the University of Maryland.Kellerman received her B.A. from Sarah Lawrence College, and her M.A. M.Phil., and Ph.D. (in Political Science) degrees from Yale University. She was awarded a Danforth Fellowship and three Fulbright fellowships. At Uppsala (1996-97), she held the Fulbright Chair in American Studies. Kellerman was cofounder of the International Leadership Association (ILA) and is author and editor of many books. Kellerman has also appeared on media outlets such as CBS, NBC, PBS, CNN, NPR, MSNBC, Reuters, and BBC, and has contributed articles and reviews to the New York Times, the Washington Post, the Boston Globe, the Los Angeles Times, and the Harvard Business Review.From 2015 to 2023, she was listed by Global Gurus as among the “World's Top 30 Management Professionals.”A Few Quotes From This Episode“He is an inveterate bad boy who is not content unless he is stirring the pot.”“Follower is the only antonym of leader we have. And sometimes followers become leaders.”“The importance of context is as real in politics as it is in organizational life.”Resources Mentioned in This Episode Barbara's BlogBook: Leader's Who Lust by KellermanBook: Bad Leadership by KellermanBook: The End of Leadership by KellermanAbout The International Leadership Association (ILA)The ILA was created in 1999 to bring together professionals interested in studying, practicing, and teaching leadership. About  Scott J. AllenWebsiteWeekly Newsletter: Practical Wisdom for LeadersBlogMy Approach to HostingThe views of my guests do not constitute "truth." Nor do they reflect my personal views in some instances. However, they are views to consider, and I hope they help you clarify your perspective. Nothing can replace your reflection, research, and exploration of the topic. ♻️ Please share with others and follow/subscribe to the podcast!⭐️ Please leave a review on Apple, Spotify, or your platform of choice.➡️ Follow me on LinkedIn for more on leadership, communication, and tech.

OA1235 - Today on Rapid Response Friday: Matt's still on island time, so it's a good-news-only kind of day as we review (1) the historic termination of deportation proceedings against Tufts grad student Rumeysa Ozturk, (2) new judicial restraints on ICE, (3) a DC federal judge's outstanding rebuke to DHS Secretary Kristi Noem's attempt to deport 350,000 Haitians, and (4) a Republican revolt on Trump's emergency tariffs. (Also: just how stupid is the super-secret memo which ICE has apparently been using to justify breaking into some immigrants' homes without a judicial warrant?) Finally in today's footnote: Matt shares how his attempt to mail some pants from the U.S. Virgin Islands revealed a weird loophole in Trump's emergency tariff orders which is now forcing some U.S. citizens to pay international duties on domestic shipments. In re: Ruiz-Massieu, Int. Dec. #3400, Board of Immigration Appeals (June 11, 1999) Whistleblower Aid letter detailing secret ICE memo allowing arrests without warrants (memo attached at Ex. 1)(Jan. 6, 2026) Sample I-205 ICE administrative warrant D.C. District Court judge Ana Reyes's decision in Moit v. Trump  preserving Temporary Protected Status for Haitians in the U.S. (2/2/2026) “Suspending Duty-Free De Minimis Treatment for All Countries,” The White House (July 30, 2025) Check out the OA Linktree for all the places to go and things to do!

Wednesday, February 11th, 2026Today, DHS officials and Howard Lutnick testify before Congress; Jamie Raskin tells Axios that Trump is in the unredacted Epstein Files over a million times; a new concentration camp in Social Circle Georgia is being met with resistance; Rep Ro Khanna read aloud the names of powerful men hidden in the Epstein Files; an FBI affidavit reveals new details about the search of the Fulton County election offices; despite Trump saying he had no knowledge of Epstein's sex crimes - he told Palm Beach police a different story in 2006; a 14 year old girl described being zip tied by ICE agents in an operation in Idaho; a judge has terminated removal proceeding for Rumeysa Ozturk; and Allison and Dana deliver your Good News.Thank You, DeleteMeGet 20% off your DeleteMe plan when you go to joindeleteme.com/DAILYBEANS and use promo code DAILYBEANS at checkout. Thank You, BrodoHead to Brodo.com/DAILYBEANS for 20% off your first subscription order and use code DAILYBEANS for an additional $10 off.  The LatestTulsi Gabbard is Covering Up a Call About Someone Close to the White House | muellershewrote.comStoriesFBI affidavit reveals new details about search of Fulton County elections office | CBS NewsNew ICE detention center in Georgia sparks outcry in Social Circle | CBS AtlantaWhat Jamie Raskin saw in the unredacted Epstein files | AxiosRümeysa Öztürk: Immigration judge terminates removal proceedings against Tufts student detained by Trump administration, attorneys say | CNNGood TroubleThe House is set to vote on a new version of the SAVE Act, Chop Roy's SAVE America Act. It has 95 cosponsors in the House (all Republicans)How The Bill Will Suppress Voters:New SAVE Act Bills Would Still Block Millions of Americans From Voting | Brennan Center for JusticeUse 5Calls to find your Representative and Senators:Oppose the SAVE America Act - HOUSE VOTE THIS WEEK | 5 Calls→How to Film ICE | WIRED→Standwithminnesota.com→Tell Congress Ice out Now | Indivisible→Defund ICE (UPDATED 1/21) - HOUSE VOTE THURSDAY→Congress: Divest From ICE and CBP | ACLU→ICE List  →iceout.org →Demand the Resignation of Stephen Miller | 5 Calls→2026 Trans Girl Scouts To Order Cookies From! | Erin in the MorningGood NewsVoteRidersIndivisible Tri-Citieshttps://www.facebook.com/profile.php?id=61574123327747Tri-Cities for Palestine (@tricities4palestine) • Instagram photos and videosWashington Immigrant Solidarity NetworkTour - DANA GOLDBERG→Go To Good News & Good Trouble - The Daily Beans to Share YoursSubscribe to the MSW YouTube Channel - MSW Media - YouTubeOur Donation LinksPathways to Citizenship link to MATCH Allison's Donationhttps://crm.bloomerang.co/HostedDonation?ApiKey=pub_86ff5236-dd26-11ec-b5ee-066e3d38bc77&WidgetId=6388736Allison is donating $20K to It Gets Better and inviting you to help match her donations. Your support makes this work possible, Daily Beans fam. Donate to It Gets Better / The Daily Beans FundraiserJoin Dana and The Daily Beans with a MATCHED Donation http://onecau.se/_ekes71More Donation LinksNational Security Counselors - Donate

In this episode I'm talking to Dr. Nicolas Rouleau, Ph.D. about his Essay An Immortal Stream of Consciousness: The scientific evidence for the survival of consciousness after permanent bodily death.This Essay was a Bigelow Institute for Consciousness Studies Essay Competition WinnerIs experience possible after death? "An immortal stream of consciousness: The scientific evidence for the survival of consciousness after permanent bodily death" was the title of Nicolas Rouleau's award-winning 2021 submission for the Bigelow Institute for Consciousness Studies' international essay competition. Adapted here as a short book, the essay describes a transmissive theory of consciousness inspired by William James and supported by experimental evidence in the field of bioelectromagnetism including the works of the author (Rouleau) and his former doctoral mentor, Michael A. Persinger. It is one of few scientific theories that reconciles physicalism with survival of consciousness after bodily death.BioDr. Nicolas Rouleau is a neuroscientist, bioengineer, and Assistant Professor of Health Sciences at Wilfrid Laurier University. He is also an Adjunct Professor of Biomedical Engineering at Tufts University and Affiliate Scientist at the Allen Discovery Center at Tufts. Dr. Rouleau was the last PhD student of Michael Persinger of Laurentian University, whose work on the electromagnetic bases of consciousness inspired Rouleau to pursue his dissertation on the material-like properties of brain tissues, including their capacity to filter electromagnetic fields. In 2017, he joined the Allen Discovery Center at Tufts University as a Postdoctoral Researcher and was a founding member of David Kaplan's Initiative for Neural Science, Disease, & Engineering at Tufts, focusing on minimal cognitive responses in bioengineered brain models.As a post-doc, Dr. Rouleau published several 3D tissue models of Alzheimer's Disease and traumatic brain injury. During the research freeze of the COVID pandemic, he wrote an award-winning essay on the topic of transmissive consciousness for the Bigelow Institute of Consciousness Studies, which garnered international attention. In 2023, Dr. Rouleau became a faculty member at Laurier and is now a PI of the Self-Organizing Units Lab (SOUL), which is supported by Tri-Council awards to investigate the mechanisms of embodied cognition and synthetic biological intelligences in customizable, bioengineered neural tissues. He also co-directs (with his colleague, Dr. Murugan) the Center for Tissue Plasticity and Biophysics (TPAB) at Laurier. He is most interested in the fundamental and scale-invariant properties of cognitive systems as well as the pursuit of unifying principles that reconcile organic neural function with analogous phenomena in cells, machines, and non-neural organisms.  https://www.bigelowinstitute.org/wp-content/uploads/2022/10/rouleau-immortal-consciousness.pdf https://www.pastliveshypnosis.co.uk/https://www.patreon.com/ourparanormalafterlifeMy book 'Verified Near Death Experiences' https://www.amazon.com/dp/B0DXKRGDFP Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Second-round of conference games continue to cause some wild results on any given night. More undefeated teams suffered first losses and long winning streaks have come to an end. It all adds up to a thrilling finish to the regular season upcoming. On Thursday's edition of Hoopsville, we check in with programs that are still clicking along well at a critical juncture of the season. What will keep them focused on their bigger goals while also avoiding any unintended bumps in the season? Guests appearing on the Hudl Hoopsville Hotline: - Scott Gyimesi & Dylan Reilly, No. 9 Tufts senior forward & junior guard - Kate Vlahakis, Manhattanville women's coach - Wendy Austin, Centre women's coach - Todd Skrivseth, Monmouth men's coach Plus, Dave's got '2-Cents' on rule changes he'd like to see administratively to the game along with a suggestion that really is a warning to teams who need to pay attention to the details. Hoopsville is presented by D3hoops.com from the WBCA Studios.

The Culture Show's Jared Bowen on a new PBS series “Breaking the Deadlock,” that explores the role of government in life and death decisions. Plus, we'll get his thoughts on the new Bradley Cooper movie “Is this thing on?” and other arts headlines.Congresswoman Ayanna Pressley discusses her calls for an independent investigation into the ICE killing in Minnesota, and for extended ACA subsidies.Tufts international affairs expert Daniel Drezner on violence in Iran – where the death toll of protesters against the regime has soared past 2,500.Food policy analyst Corby Kummer on the closing of Time Out Market in Fenway, the environmental impact of the new dietary guidelines and how restoring wild oyster reefs in Massachusetts is a win for conservationists and seafood bars. Dr. Atul Gawande is the former assistant administrator for global health at USAID. He explains how the shutdown of the aid organization has had ripple effects around the world…including contributing to the deaths of over half a million people worldwide, most of them children. It's the topic of his Oscar-shortlisted documentary “Rovina's Choice.”

Tufts University's international affairs scholar Daniel Drezner on the United States' weekend invasion of Venezuela to depose its authoritarian leader, Nicolas Maduro. Tufts food policy analyst Corby Kummer forecasts 2026 food trends and how to stick to New Year's resolutions. Plus, he updates us on how the Trump administration's agriculture investments will impact farmers. Bioethicist Dr. Ezekiel Emanuel discusses his new book “Eat Your Ice Cream: Six Simple Rules for a Long and Healthy Life.”There are more lawmakers of color than ever on Beacon Hill. But the legislature still remains disproportionately white. We talk to Mass League of Community Health Center's Michael Curry about that, and what a boost in rural health system federal funding could mean for western Mass.